Scholars Academic Journal of Pharmacy
Abbreviated Key Title: Sch Acad J Pharm
ISSN 2347-9531 (Print) | ISSN 2320-4206 (Online)
Journal homepage: http://saspublishers.com

OPEN ACCESS

Zoology

Convergence at the Nanoscale: Transformative Advances in Drug Delivery, Vaccinology, and Biomedical Diagnostics

Position Irfan Ishaque[1], Ayesha Aslam[2*], Muhammad Ramzan Ali[3], Muhammad Asim Zafar Khan[4], Amna Shakeel[5], Shah Faisal Ghani[6], Ayesha Suleman[7], Ariba Asif[8], Khadija Amjad[9], Sehar Rafique[10]

[1]Department of Zoology, Government College University, Lahore, Punjab 54000, Pakistan
[2]Department of Biochemistry, University of Okara, Punjab, Pakistan
[3]DVM (Doctor of Veterinary Medicine), Riphah International University, Islamabad Riphah College of Veterinary Sciences, Lahore
[4]Institute of Microbiology, University of Agriculture, Faisalabad, Punjab 54470, Pakistan
[5]Department of Pharmacy, Government College University, Faisalabad, Punjab, Pakistan
[6]Department of Pharmacy, Quaid-i-Azam University, Islamabad, Pakistan
[7]Department of Zoology, Aspire Group of Colleges, Jhelum, Punjab 50000, Pakistan
[8]Department of Zoology, Aspire Group of Colleges, Jhelum, Punjab 50000, Pakistan
[9]Department of Zoology, Aspire Group of Colleges, Jhelum, Punjab 50000, Pakistan
[10]Department of Zoology, Division of Science and Technology, University of Education, Lahore, Punjab 54470, Pakistan

DOI: https://doi.org/10.36347/sajp.2025.v14i06.004 | **Received:** 21.05.2025 | **Accepted:** 16.08.2025 | **Published:** 18.08.2025

***Corresponding author:** Ayesha Aslam
Department of Biochemistry, University of Okara, Punjab, Pakistan

Abstract **Review Article**

Nanotechnology has become a disruptive technology in the field of medicine delivering solutions in diagnostics, therapeutics and vaccine development in a precise manner. The article gives a broad understanding of the development, processes and medical utilization of nanomaterial's namely liposomes, dendrimers, polymeric carriers, and quantum dots as drug delivery and biosensing systems. Nano diagnostics in the form of lab-on-a-chip (LOC) and point-of-care (POC) testing holds tremendous potential in terms of determining pathogens quickly and multiplexed along with monitoring chronic conditions. An example of how nanomedicine is working in the real world occurred with the COVID-19 pandemic, which catalyzed the development of gold and magnetic nanoparticle-based diagnostics platforms into the field and mRNA-based vaccines. Notwithstanding these developments, there is still a set of troubles associated with scalability of manufacturing, standardization of regulations and ethical governance. The major ethical concerns are human enhancement, surveillance, and inequality in access to high-tech means on the global level. The article also discusses new technologies called DNA origami, nanobots and biohybrids-the ones which are expected to disrupt the precision medicine with the use of programmable and flexible systems. Being combined with genomics and systems biology, intelligent therapeutics that have dynamic molecular response are under way. Nevertheless, biocompatibility, autonomous regulation, and ostensibly fair use top modules are still subject to questioning. These grand challenges need multidisciplinary teamwork, a solid ethical ground, and convergence in regulatory approaches. The vision that was envisioned in this future is the ability of self-powered, AI-enabled Nano devices, providing real-time feedback, and able to transition the healthcare industry to a decentralized and personalized paradigm. The convergence of scientific novelty and social clarification emphasized in this synthesis are what drive forces in the advancement of Nano medicine.

Keywords: nanomedicine, nanodiagnostics, DNA origami, human enhancement, point-of-care, personalized healthcare.

1. INTRODUCTION

Nanotechnology is the science and engineering of manipulating materials at the nanometer scale, typically ranging from 1 to 100 nanometers, where quantum effects and surface phenomena begin to dominate material behaviour. At this scale, materials exhibit radically different physical, chemical, and biological properties compared to their macroscale counterparts. This unique behavior underpins the promise of nanomedicine, which uses nanoscale tools and materials for diagnosing, treating, and preventing disease with unprecedented precision and efficacy. According to Patel et al. (2021), nanotechnology in medicine leverages the enhanced surface-to-volume ratios, electron quantum confinement, and reactivity of nanoparticles to create novel therapeutic and diagnostic strategies. In the field of pharmaceuticals, this translates

into more targeted drug delivery, controlled release mechanisms, and lower systemic toxicity. As nanotechnology continues to mature, its applications in biosensors, imaging agents, surgical tools, and tissue engineering are also expanding rapidly. The scope of nanomedicine has broadened to include multiple domains such as oncology, cardiology, neurology, and infectious disease. Recent reviews highlight the versatility of nanostructures—such as liposomes, dendrimers, carbon nanotubes, and metal nanoparticles—across diverse medical applications. These nanostructures can traverse biological barriers, bind specifically to disease biomarkers, and respond to stimuli such as pH or temperature to release their therapeutic payloads only at diseased sites. Despite these advances, the potential hazards of nanomaterials have also drawn attention. Kalangi and Bhosale (2022) emphasize that toxicity testing for nanotherapeutics is still in its infancy, and there is a growing need to balance innovation with safety and biocompatibility.

The theoretical foundation of nanotechnology traces back to Richard Feynman's visionary 1959 lecture, "There's Plenty of Room at the Bottom." However, it wasn't until the 1980s and 1990s, with the invention of the scanning tunneling microscope and the discovery of fullerenes, that nanotechnology began to transition from theory to practice. The first clinical application of nanotechnology in medicine came in 1995 with the approval of Doxil®, a liposomal formulation of doxorubicin. This milestone demonstrated the power of nanocarriers to reduce toxicity and increase efficacy in chemotherapy. Since then, the field has seen an explosion of research and development, especially after 2010, when the term "nanomedicine" gained prominence in academic and industrial spheres. A bibliometric study by Lam (2022) analyzing over 50,000 cancer nanotechnology papers noted an exponential increase in nanoparticle-based research since 2010, with a peak growth rate between 2017 and 2021. Key areas of development included iron oxide nanoparticles, mesoporous silica particles, and nanotechnology for DNA/RNA-based therapeutics. Nanomedicine has also been increasingly integrated into surgical oncology. For example, fluorescence-conjugated nanoparticles have been utilized to guide tumor resections, increasing precision and patient survival outcomes.

Nanotechnology is inherently interdisciplinary. Its development has been driven by a convergence of innovations in chemistry, physics, and biology, leading to an entirely new class of hybrid medical technologies. Chemistry provides the synthetic pathways for engineering nanoparticles with tailored surface chemistries. This allows for targeted delivery, solubility tuning, and triggered release based on environmental stimuli. Physics contributes fundamental principles of quantum mechanics, optics, and magnetism—essential for developing quantum dots, magnetic nanoparticles, and nano-imaging systems. Biology informs the mechanisms of cellular uptake, protein corona formation, immunogenicity, and biocompatibility—all crucial for translating nanosystems into therapeutic reality. Recent work also underscores how bio-inspired nanotechnology—drawing from nature's own nanoscale machinery—has led to advances like DNA-origami-based nanopores for single-molecule detection and lipid-coated nanostructures for drug delivery. This convergence is further reflected in the development of nanosimilars, which mimic first-generation nanomedicines but introduce complexities in regulatory assessment due to the sensitivity of nanostructure performance to manufacturing variations. As the field advances, nanotechnology is not only creating novel treatment platforms but also reshaping how diseases are understood and managed at the molecular level. With every new material, diagnostic tool, or therapeutic agent, the boundaries between disciplines become increasingly blurred by the deeply integrated nature of nanomedical innovation.

1. Fundamentals of Nanomaterials in Biomedical Applications

1.1. Classification: Organic, Inorganic, and Hybrid Nanoparticles:

Nanotechnology has emerged as a transformative force in modern biomedicine, enabling the development of novel materials at the nanometer scale that interact with biological systems in highly specific and effective ways. One of the foundational pillars of nanomedicine is the classification of nanomaterials based on their composition and structural origin—namely organic, inorganic, and hybrid nanoparticles. Each of these categories brings unique characteristics that shape their biomedical functionality, performance, and clinical viability. As illustrated in Figure 1, nanoparticles used in biomedical applications can be broadly classified into three principal categories: organic nanoparticles, which are carbon-based and include liposomes, micelles, dendrimers, and polymeric nanoparticles; inorganic nanoparticles, composed of metals or metal oxides such as gold and iron oxide nanoparticles; and carbon-based nanoparticles, including fullerenes, graphene, and carbon nanotubes, which form a transitional class with both organic and inorganic characteristics, often grouped within hybrid or standalone inorganic materials depending on the context. This figure not only provides visual clarity but also highlights the structural diversity of nanomaterials and sets the stage for a nuanced understanding of their biomedical implications.

Organic nanoparticles are composed of biodegradable and biocompatible materials—such as lipids, natural or synthetic polymers—that make them especially suitable for drug delivery, vaccine formulation, and gene therapy. Their chemical nature allows for functionalization with targeting ligands and the encapsulation of hydrophilic and hydrophobic agents. Liposomes, spherical vesicles with one or more

phospholipid bilayers, mimic the structure of biological membranes, making them excellent carriers for drugs and genetic material. Their success is underscored by FDA-approved products such as Doxil®, a pegylated liposomal formulation of doxorubicin for cancer therapy. Liposomes can passively accumulate in tumor tissues via the enhanced permeability and retention (EPR) effect and can be surface-modified for active targeting (Yanar *et al.,* 2023). Micelles, on the other hand, are self-assembled colloidal structures with a hydrophobic core and hydrophilic shell, ideal for solubilizing poorly water-soluble drugs. They exhibit high loading capacity and can respond to pH, temperature, or enzymatic conditions in diseased tissues for controlled release. Polymeric nanoparticles, often made from poly(lactic-co-glycolic acid) (PLGA), polycaprolactone (PCL), or chitosan, offer tailored drug release profiles and protect encapsulated agents from enzymatic degradation. Their biodegradability and safety profiles have made them a staple in sustained drug delivery systems. Dendrimers are branched, tree-like polymers with a high degree of surface functionality. Their architecture allows for multivalent interactions with drugs, targeting ligands, or imaging agents. Because of their precise size and monodispersity, dendrimers are particularly useful for targeted delivery of genes and chemotherapeutic agents (Mehta *et al.,* 2022).

Inorganic nanoparticles are composed of metals or metal oxides and are often characterized by their unique optical, magnetic, or electronic properties. These properties make them invaluable for applications in bioimaging, diagnostics, and photothermal/photodynamic therapy. Gold nanoparticles (AuNPs) are among the most extensively studied for medical use due to their surface plasmon resonance (SPR), which allows for strong light absorption and scattering. This feature makes them ideal for photothermal therapy (PTT), where laser-induced heating ablates tumor cells, and also for biosensing applications. Iron oxide nanoparticles (IONPs), specifically superparamagnetic iron oxide nanoparticles (SPIONs), are widely used as MRI contrast agents. Their superparamagnetic behavior also enables magnetic drug targeting and hyperthermia treatments. Coating with biocompatible materials such as dextran or PEG further improves their systemic circulation and reduces aggregation. Quantum dots (QDs) are semiconductor nanoparticles with unique fluorescence properties. They offer long-term photostability and tunable emission spectra, making them powerful tools for molecular imaging and multiplexed diagnostics. However, concerns regarding the heavy metal content of QDs, such as cadmium, have led to the development of safer alternatives using silicon or carbon-based cores. Metal oxide nanoparticles such as zinc oxide (ZnO) and titanium dioxide (TiO_2) possess photocatalytic activity and have been used in antimicrobial therapies and bioimaging. Their biocompatibility varies depending on particle size, surface charge, and functionalization, which must be carefully optimized to reduce cytotoxic effects (Yang *et al.,* 2021).

Carbon-based nanostructures—including fullerenes, graphene, and carbon nanotubes (CNTs)—are exceptional due to their mechanical strength, electrical conductivity, and surface area. These properties allow them to interact with cellular systems, deliver therapeutic agents, and act as scaffolds for tissue engineering. Fullerenes (C_{60}) possess antioxidant properties and can scavenge reactive oxygen species (ROS), making them candidates for neuroprotective therapies. Carbon nanotubes, when functionalized, can cross biological membranes and deliver genes or drugs directly into cells. Graphene and graphene oxide offer large surface areas for drug loading and are being investigated in biosensors and regenerative medicine. These nanoparticles blur the boundary between organic and inorganic systems and are often included in the hybrid category when combined with other functional elements.

Hybrid nanoparticles integrate the benefits of organic and inorganic nanomaterials into a single platform. These include liposomes or polymers encapsulating inorganic cores (e.g., quantum dots, iron oxide), inorganic shells surrounding organic drug carriers, and co-assembled structures, where organic and inorganic components are integrated through physical or chemical interactions. Such systems enable multifunctionality: imaging, targeting, and therapy in a single nanostructure (i.e., theranostics). For instance, gold nanoshells encapsulated in liposomes can enable simultaneous imaging and photothermal ablation. Similarly, iron oxide nanoparticles embedded in PLGA nanoparticles allow for MRI-guided drug delivery. These systems also show enhanced bioavailability, prolonged circulation time, and reduced immunogenicity, especially when surface-modified with polyethylene glycol (PEG) or cloaked in biological membranes (Park *et al.,* 2020). Recent innovations (2019–2025) include stimuli-responsive hybrid nanoparticles that release drugs in response to pH, enzymes, or temperature, and self-assembling nanostructures that form in situ within biological environments for precision delivery (Yanar *et al.,* 2023).



Figure 1: Classification of Biomedical Nanoparticles: Organic, Inorganic, and Hybrid Systems

This figure categorizes nanoparticles commonly used in medicine into three main types—organic (e.g., liposomes, dendrimers), inorganic (e.g., gold nanoparticles, iron oxide), and hybrid systems that combine features of both. It highlights their unique structural properties, functionalization potential, and typical applications such as drug delivery, imaging, or gene therapy.

1.2. Physicochemical Properties Relevant to Medical Use:

In biomedical applications, nanoparticles are required to traverse a complex physiological environment, including immune defense mechanisms, cellular barriers, and the intricacies of targeted delivery. Their in vivo performance is not determined solely by material composition but by a spectrum of physicochemical properties—such as size, shape, surface charge, hydrophobicity, surface chemistry, material composition, and behavior upon exposure to biological fluids. These characteristics significantly affect the circulation time, biodistribution, cellular uptake, and overall therapeutic efficacy of nanomedicines. As illustrated in Figure 2, a thorough understanding and precise engineering of these parameters are essential to optimize nanoparticle function while minimizing toxicity and unintended interactions.

Among these properties, particle size plays a pivotal role. Nanoparticles typically fall within the 1–100 nm range, though biological relevance can extend to particles as large as 200 nm. Size governs key behaviors such as renal clearance, tissue penetration, and cellular internalization pathways. Particles smaller than 5–6 nm are rapidly excreted via the kidneys, making them ideal for diagnostic imaging but unsuitable for prolonged drug delivery. Nanoparticles in the 10–100 nm range exhibit favorable biodistribution, often evading clearance by the mononuclear phagocyte system (MPS) and passively accumulating in tumors through the enhanced permeability and retention (EPR) effect. In contrast, particles larger than 200 nm tend to be sequestered in the liver and spleen, thereby reducing systemic circulation and increasing the likelihood of off-target accumulation. Furthermore, particle size influences the surface area-to-volume ratio, which in turn affects drug loading capacity and release profiles (Moraes *et al.,* 2021; Talkar *et al.,* 2018).

The shape of nanoparticles further modulates their in vivo behavior. Common geometries include spheres, rods, stars, cubes, and plates. Spherical particles are most widely used due to their straightforward synthesis and efficient cellular uptake. However, rod-shaped and filamentous particles often demonstrate enhanced margination along blood vessel walls and improved tumor penetration, attributed to increased membrane contact areas. Some flat-shaped particles, such as disks or plates, display faster clearance and reduced uptake. Moreover, recent studies reveal that rod- and filament-like particles can bypass clathrin-mediated endocytosis, facilitating deeper tissue infiltration and prolonged retention (Rahman *et al.,* 2013; John, 2023). Surface charge, usually expressed as zeta potential, is another critical determinant of nanoparticle behavior. Positively charged nanoparticles are more readily

internalized by cells due to electrostatic attraction to the negatively charged cellular membranes; however, they are also more likely to induce cytotoxicity and non-specific binding. Neutral or negatively charged nanoparticles typically circulate longer and elicit fewer immune responses (Singh, 2016). Surface charge also influences protein adsorption—the formation of a "protein corona"—which can significantly alter the biological identity and fate of nanoparticles in circulation (Talkar *et al.,* 2018).

Surface chemistry and functionalization are equally vital in determining how nanoparticles interact with biological environments. The presence of functional groups such as -SH, -NH_2, and -COOH facilitates the conjugation of therapeutic agents, imaging molecules, and targeting ligands. Polyethylene glycol (PEG) coatings, a widely adopted modification, help nanoparticles evade immune detection, prolong blood half-life, and enhance solubility. Targeting moieties such as antibodies, peptides, or aptamers can be tethered to the surface to enable active targeting of disease-specific markers (Utreja *et al.,* 2020). As represented in Figure 2, such surface modifications are tailored to a range of biomedical applications including targeted drug delivery, photothermal therapy, and MRI contrast enhancement.Hydrophobicity and colloidal stability are additional properties influencing nanoparticle fate. Highly hydrophobic particles tend to aggregate in aqueous environments and are more prone to rapid immune clearance. Increasing hydrophilicity—via polymer coatings or surface treatment—can enhance colloidal stability, prevent aggregation, reduce nonspecific interactions, and support prolonged circulation in blood. Stable colloidal behavior is essential for consistent dosing, predictable bio-distribution, and avoiding clogging in capillaries or microvasculature (Zolnik *et al.,* 2010).

Material composition and crystalline structure directly impact the mechanical, optical, and magnetic behavior of nanoparticles. The selection of core materials such as gold, silica, or iron oxide depends on the intended application. Gold nanoparticles, for instance, are prized for their strong optical absorption properties and are often used in photothermal therapy and imaging. Magnetic nanoparticles like iron oxide function as MRI contrast agents and are also explored for magnetically guided delivery systems. Quantum dots, known for their tunable fluorescence, are powerful imaging tools though they raise toxicity concerns due to the presence of heavy metals (Rahman *et al.,* 2013; Talkar *et al.,* 2018).Finally, the phenomenon of protein corona formation—whereby circulating proteins adsorb onto nanoparticle surfaces—can drastically redefine the biological identity of nanoparticles. This layer may obscure targeting ligands, change cellular uptake behavior, and redirect biodistribution pathways. While stealth coatings such as PEG can minimize corona formation, some approaches purposefully manipulate it for biomimicry or immune evasion strategies. Thus, characterizing and controlling the protein corona is now viewed as essential for accurately predicting nanoparticle behavior in vivo and for the successful design of clinical nanomedicines.



Figure 2: Key Physicochemical Attributes Influencing Nanoparticle Behavior in Biological Systems

Illustrated here are the core physicochemical properties of nanoparticles—size, shape, surface charge, hydrophobicity, and surface chemistry—that critically affect circulation time, cellular uptake, biodistribution, and therapeutic performance. These factors determine how effectively a nanomaterial can be tailored for specific medical applications.

1.3. Biocompatibility and Toxicological Considerations

The remarkable versatility of nanoparticles (NPs) in medicine is paralleled by rising concerns about their biocompatibility and potential toxicity. While nanomaterials have facilitated breakthroughs in targeted drug delivery, imaging, and diagnostics, their small size, high surface area, and unique surface characteristics may lead to unintended biological consequences. As illustrated in Figure 3, the interplay of nanoparticle composition, surface modifications, and degradation kinetics fundamentally shapes their fate in biological systems, influencing protein corona formation, immune recognition, phagocytic uptake, and their therapeutic or toxicological profiles. The composition of a nanoparticle's core determines its chemical reactivity and biodegradability, both of which are critical to tissue compatibility. Metal-based NPs, such as silver, gold, and titanium dioxide, often induce reactive oxygen species (ROS), promoting oxidative stress, inflammation, or apoptosis in both target and non-target tissues. In contrast, polymeric and lipid-based NPs generally exhibit greater biocompatibility because they degrade into non-toxic metabolites. Biodegradable polymers like PLGA, PCL, and PEG derivatives are widely favored for sustained drug release due to their mechanical stability and reduced risk of metal ion leaching, which might otherwise contribute to organ-specific accumulation and cytotoxicity. A key biological interaction is the formation of a protein corona upon NP exposure to blood plasma. This corona, composed of a tightly bound inner layer and a loosely associated outer layer of biomolecules, redefines the particle's biological identity, influencing immune cell interactions and organ distribution. Opsonization, as visualized in Figure 3, flags nanoparticles for macrophage uptake, limiting their circulation and redirecting them to the liver and spleen. Strategies such as PEGylation, polysaccharide coatings, and cell membrane cloaking are employed to reduce immune recognition and extend circulation times.

The degradation rate of nanoparticles further determines their biological persistence and toxicity. Slow or non-degradable NPs can accumulate in tissues, potentially leading to chronic inflammation, fibrosis, or genotoxic effects. Gold nanoparticles, for instance, though generally biocompatible, degrade slowly and may remain in tissues for extended periods. Silica and carbon-based particles, if not surface-functionalized, have been associated with lung inflammation, especially upon inhalation. In contrast, lipid and protein-based nanoparticles degrade into harmless byproducts, presenting lower systemic risks. Cytotoxicity often results from oxidative stress via ROS generation, mitochondrial dysfunction, lysosomal leakage, and DNA damage, which may lead to mutagenesis or carcinogenesis. These outcomes depend significantly on particle size, charge, and composition; particles smaller than 10 nm are more likely to enter the nucleus, and positively charged NPs generally exhibit stronger, and often more harmful, interactions with cell membranes. Nanoparticles also interact with the immune system in complex ways.

They may activate pro-inflammatory responses, stimulate complement pathways, or provoke cytokine release. Nonetheless, well-designed NPs with biocompatible coatings such as albumin or phospholipids can avoid immune detection and maintain therapeutic efficacy. As Figure 3 shows, poorly designed NPs are more readily phagocytosed and cleared, while stealth-modified particles preserve circulation time. Organ-specific toxicities have been documented, with the liver and spleen being the primary accumulation sites after intravenous delivery, and the kidney and bladder playing major roles in excretion, particularly for particles under 6 nm. Inhalation of NPs, especially in industrial settings, is associated with pulmonary toxicity, while neurotoxicity arises from the ability of some particles to breach the blood–brain barrier, causing neural inflammation or damage. Accordingly, understanding biodistribution and toxicokinetics is vital for safe clinical translation. Emerging testing methods go beyond traditional assays like MTT and LDH release, integrating omics technologies to detect stress biomarkers and using zebrafish or organoid models for system-level toxicology.

Furthermore, machine learning is being adopted to predict nanoparticle behavior based on physicochemical traits, enhancing the design of safer materials. As demonstrated in Figure 3, a nanoparticle's clinical potential is inherently linked to its core composition, surface design, and biodegradability. These factors determine immune interactions, circulation, and therapeutic versus toxic outcomes. Thus, the rational design of biocompatible nanomaterials requires a deep understanding of how nanoparticles behave at both the cellular and systemic levels. With sustained interdisciplinary research and innovations in safety testing, the goal of safe and effective nanomedicine is steadily becoming a reality.



Figure 3: Interplay Between Nanoparticle Composition and Biological Response

This figure outlines how material composition, surface modifications, and degradation kinetics influence a nanomaterial's biocompatibility and toxicity. It depicts common biological interactions, including protein corona formation, immune activation, and potential cytotoxicity, which are key for clinical translation of nanomedicine.

2. Nanotechnology-Driven Drug Delivery Systems:

2.1. Liposomes, Dendrimers, and Polymeric Nanocarriers

Nanotechnology has revolutionized drug delivery systems by enabling the development of nanoscale carriers such as liposomes, dendrimers, and polymeric nanoparticles, which offer enhanced solubility, targeted delivery, and controlled release of therapeutic agents. These innovations significantly improve the safety and efficacy of medical formulations, particularly in the treatment of complex diseases. Liposomes, which are spherical vesicles composed of one or more phospholipid bilayers surrounding an aqueous core, are biocompatible and capable of encapsulating both hydrophilic and hydrophobic drugs. Their structural resemblance to biological membranes facilitates cellular uptake and reduces immune response. Clinically, liposomes have already demonstrated their value—most notably in the FDA-approved PEGylated liposomal formulation of doxorubicin (Doxil®) used in cancer therapy. Surface modification with polyethylene glycol (PEG) extends circulation time, while the addition of ligands such as antibodies or peptides enables targeted delivery to disease-specific receptors. Recent research emphasizes the utility of stimuli-responsive liposomes that release their payload in response to tumor-associated conditions such as pH, temperature, or enzyme activity, thereby enhancing therapeutic precision and reducing collateral damage to healthy tissues (Haider, 2024; Mohapatra *et al.,* 2024). Liposomes are particularly important in cancer treatment, gene delivery, and vaccine development, where they not only enhance drug stability but also protect sensitive molecules like siRNA and mRNA from enzymatic degradation.

Dendrimers, on the other hand, are highly branched, monodisperse macromolecules with a central core and numerous surface functional groups, enabling multifunctional applications. Their architecture permits the simultaneous conjugation of multiple drug molecules, targeting moieties, and imaging agents. Commonly studied dendrimers such as polyamidoamine (PAMAM) and polypropylene imine (PPI) have been applied in gene delivery, taking advantage of their positive surface charges to bind and protect nucleic acids. They have also shown promise in targeted cancer therapy, using ligands that bind to overexpressed receptors like folate or HER2, and in antibiotic delivery

by improving intracellular penetration and reducing microbial resistance. However, their clinical translation is complicated by dose-dependent toxicity associated with their cationic surfaces, which can disrupt cellular membranes. Advances in dendrimer engineering, including the incorporation of biodegradable linkages, have shown potential in reducing cytotoxicity and improving safety profiles for in vivo use (Kumar *et al.,* 2024).

Polymeric nanocarriers, including nanoparticles, micelles, nanogels, and polymersomes, are constructed from biodegradable polymers such as PLGA, PEG, or PCL, and are valued for their structural flexibility and functional versatility. These carriers enable controlled and sustained drug release, shielding the encapsulated agents from degradation and allowing for surface modifications that confer either stealth properties or active targeting capabilities. They are especially effective for delivering poorly soluble small molecules, proteins, and nucleic acids, enhancing bioavailability and reducing systemic toxicity. Recent developments highlight polymer-based carriers that respond to physiological stimuli such as pH gradients or redox potential, improving targeted delivery to hypoxic tumor microenvironments (Haider, 2024; Mohapatra *et al.,* 2024). Among these, micelles formed from amphiphilic block copolymers are notable for their ability to solubilize hydrophobic drugs and for their small size (typically 10–100 nm), which facilitates deep tissue penetration.

Each type of nanocarrier possesses unique advantages. Liposomes excel in encapsulating both hydrophilic and hydrophobic drugs and have a strong clinical track record. Dendrimers offer high functionality and precision targeting due to their tunable surface chemistry, while polymeric nanoparticles provide structural adaptability, efficient drug loading, and scalable manufacturing potential. Cutting-edge research increasingly integrates features from these distinct systems to create hybrid nanostructures, such as polymer-coated liposomes or dendrimer-micelle composites, which improve multifunctionality and enhance biological performance by overcoming physiological barriers (Shaik & Y, 2022). The clinical relevance of these platforms continues to grow, especially in the context of personalized medicine for oncology and infectious diseases.

Emerging trends include the use of smart drug delivery systems that activate upon biological or external triggers (e.g., heat, light), the development of theranostic nanocarriers that combine therapeutic and diagnostic functions, and the creation of bioinspired delivery systems, such as cell membrane-coated nanoparticles that evade immune recognition (Wu *et al.,* 2024). Nonetheless, challenges remain—most notably in achieving consistent manufacturing, scalability, biocompatibility, and meeting regulatory standards. Despite these hurdles, interdisciplinary advances in nanotechnology, materials science, and biomedical engineering are steadily accelerating the clinical adoption of nanocarriers, particularly for cutting-edge therapies like gene editing and immunomodulation. In conclusion, liposomes, dendrimers, and polymeric nanoparticles represent the leading edge of nanomedicine. Their sophisticated architectures, customizable properties, and potential to address limitations of conventional therapies position them as ideal vehicles for the next generation of targeted, safe, and effective therapeutic solutions.

2.2. Controlled Release and Targeted Drug Delivery Mechanisms

Conventional drug delivery methods are often plagued by shortcomings such as rapid systemic clearance, poor solubility, non-specific biodistribution, and insufficient therapeutic concentrations at the disease site. Nanotechnology has dramatically reshaped this scenario by enabling both controlled release and targeted delivery of therapeutic agents, resulting in smarter, more efficient, and safer treatment modalities. Nanocarriers can be precisely engineered to release drugs at specific locations, at defined rates, and in response to internal or external biological triggers. These advancements enhance treatment efficacy while reducing adverse effects and improving patient adherence.

Controlled drug release refers to the ability of a delivery platform to regulate the timing, rate, and spatial location of drug administration. Nanoscale technologies achieve this by encapsulating therapeutic compounds in nanocarriers that protect them from premature degradation, incorporating stimuli-responsive materials that react to environmental cues such as pH, temperature, redox conditions, or enzymes, and through surface modifications that enable prolonged systemic circulation or selective release at the disease site. Kumar et al. (2024) outlined multiple mechanisms for drug release, including diffusion-controlled, erosion-controlled, and osmotic systems, all of which allow for fine-tuned therapeutic delivery.

Targeted drug delivery can be categorized into passive and active strategies. Passive targeting leverages the Enhanced Permeability and Retention (EPR) effect, which is characteristic of tumor vasculature that allows nanoparticles within the 10–200 nm range to accumulate preferentially. Clinically approved formulations like Doxil® and Abraxane® utilize this mechanism to deliver chemotherapy more precisely, thereby minimizing systemic toxicity (Bajaj & Davu, 2024). Active targeting, on the other hand, involves decorating nanocarrier surfaces with ligands such as antibodies, peptides, or aptamers that bind specifically to receptors overexpressed on diseased cells. Examples include folate receptor targeting in breast and ovarian cancer, transferrin receptor targeting for brain delivery, and RGD peptide targeting of angiogenic blood vessels. Such

modifications significantly improve cellular uptake while minimizing off-target effects, making them especially useful in cancer and neurological applications.

A transformative advancement in this field is the development of stimuli-responsive or "smart" nanocarriers that release their therapeutic payload only upon encountering specific triggers. Internal stimuli-responsive systems are designed to release drugs under conditions like low pH in tumor environments or within endosomes, or in the presence of elevated intracellular glutathione (GSH) levels that break disulfide bonds in redox-responsive carriers. Others rely on enzymatic activation by matrix metalloproteinases (MMPs) that are commonly overexpressed in cancerous tissues (Raheem, 2024). External stimuli-triggered systems include nanocarriers activated by light, magnetic fields, ultrasound, or temperature changes, providing non-invasive ways to control drug delivery spatiotemporally and enhance localized therapeutic action (Zhang *et al.,* 2014).

Hybrid systems that integrate controlled release with targeting functionalities are becoming increasingly prevalent. These platforms often involve core–shell nanoparticles, where one layer stores the drug and another controls its release, or mesoporous silica particles loaded with therapeutic agents and sealed with disintegrable capping ligands that respond to specific stimuli. Ligand-exchange-triggered platforms, for example, use molecules like EDTA or citrate to disrupt the capping layer only under desired conditions, releasing the drug precisely at the pathological site (Teng *et al.,* 2012). Such systems demonstrate exceptional specificity for cancer cells while sparing healthy tissue.

Polymer-based nanocarriers—including polymeric nanoparticles and nanogels—offer structural flexibility and customizable degradation profiles. Biodegradable polymers such as PLGA, PEG, and PCL allow sustained drug release over hours or even weeks, depending on the application. Innovations include micelles with hydrophobic cores that solubilize poorly water-soluble drugs and responsive outer shells that react to changes in the biological environment. Nanogels, composed of crosslinked hydrophilic polymer networks, are particularly suitable for swelling or degrading in response to local stimuli like pH or redox shifts (Gupta & Sharma, 2024). These platforms are increasingly applied in chronic disease management, including diabetes, cardiovascular conditions, and persistent infections.

The utility of controlled and targeted nanocarriers has been most prominently demonstrated in oncology, where localized drug delivery significantly reduces systemic toxicity. Nanoformulations like Doxil®, Abraxane®, and Genexol-PM have already gained regulatory approval, validating the clinical impact of these technologies. In neurology, nanocarriers functionalized with transferrin or polysorbate have shown enhanced blood–brain barrier permeability, enabling targeted delivery of neuroprotective agents or antipsychotics (Bajaj & Davu, 2024). In cardiology, nanocarriers sensitive to pH and oxidative stress are being tailored to deliver thrombolytics or antioxidants in models of myocardial infarction and stroke, providing site-specific protection against ischemic injury (Raheem, 2024).

Despite these advancements, several challenges remain in the path to widespread clinical application. These include difficulties in scaling up production under Good Manufacturing Practice (GMP) conditions, ensuring reproducibility of drug loading and release profiles, navigating complex regulatory frameworks due to the intricate structure–activity relationships of nanocarriers, and addressing concerns regarding long-term toxicity—especially for non-degradable materials. Nevertheless, progress in biomimetic engineering, predictive computational modeling, and quality-by-design manufacturing frameworks continues to address these issues, accelerating the safe and effective integration of nanocarrier systems into mainstream clinical practice.

2.3. **Overcoming Biological Barriers: BBB, Tumor Microenvironment, and Intracellular Uptake**

One of the most formidable challenges in drug delivery—particularly for neurological and oncological diseases—is posed by biological barriers that prevent therapeutic agents from effectively reaching their targets. Among the most critical of these are the blood–brain barrier (BBB), the tumor microenvironment (TME), and the intracellular transport processes that regulate cellular entry and localization. Nanotechnology provides innovative strategies to navigate or exploit these barriers, facilitating precise, efficient, and minimally invasive therapies. The BBB, a tightly regulated endothelial interface, protects the central nervous system (CNS) but also restricts approximately 98% of traditional therapeutic agents from entering the brain. To overcome this, several nanoparticle-based strategies have been developed. Polysorbate 80-coated nanoparticles, for instance, mimic low-density lipoprotein (LDL) particles by adsorbing apolipoproteins and undergo receptor-mediated transcytosis across endothelial cells via LDL receptors (Kreuter, 2021). Similarly, nanoparticles modified with apolipoprotein E (ApoE) utilize LDL receptor-related proteins for active uptake, significantly enhancing drug delivery into the brain (Wagner *et al.,* 2012). Layer-by-layer (LbL) nanoparticles with surface coatings such as hyaluronic acid also improve BBB transport by modulating endocytosis and exocytosis pathways, with surface stiffness playing a critical role in trafficking efficiency (Lamson *et al.,* 2022). Beyond nanoparticle design, other innovative strategies such as focused ultrasound with microbubbles can transiently disrupt the BBB to facilitate entry, while intranasal delivery exploits neural pathways to bypass systemic

circulation. Additionally, magnetic targeting using superparamagnetic particles directed by external magnetic fields presents another effective approach for enhancing CNS drug localization (Lim *et al.,* 2024).

The tumor microenvironment presents an equally complex challenge. Characterized by abnormal vasculature, dense extracellular matrix (ECM), hypoxia, and immune suppression, the TME restricts nanoparticle diffusion, cellular uptake, and drug retention. Elevated interstitial fluid pressure limits passive diffusion, while dense ECM architecture impedes movement of larger or rigid particles. Furthermore, hypoxic regions and acidic pH hinder drug activity and uptake, and drug efflux proteins like P-glycoprotein actively expel drugs from tumor cells. To address these challenges, nanocarriers have been engineered to exploit the unique conditions of the TME. Size-tunable nanoparticles in the 10–100 nm range allow deeper penetration into tumor tissues while evading renal clearance (Kang *et al.,* 2018). pH-sensitive carriers selectively release drugs in the acidic tumor milieu, while enzyme-responsive nanoparticles degrade in the presence of tumor-specific enzymes such as matrix metalloproteinases (MMPs). More advanced systems rely on endogenous tumor signals, such as glutathione or hypoxia, to trigger site-specific drug release, enhancing efficacy while minimizing systemic toxicity (Bor & Hosta-Rigau, 2023).

Even when therapeutic agents reach their target tissues, effective intracellular uptake remains essential for their biological action. Cell membranes tightly regulate foreign material entry, and many nanocarriers become trapped in endosomes, where their cargo may be degraded before reaching its intended site. To enhance uptake, nanocarriers are functionalized with ligands—such as antibodies, aptamers, or peptides—that promote receptor-mediated endocytosis. Additionally, cell-penetrating peptides (CPPs) are used to facilitate direct translocation across membranes. Some systems employ pH-sensitive polymers that destabilize endosomal membranes under acidic conditions, enabling escape into the cytoplasm. Upconversion nanoparticles (UCNPs) represent a unique platform that combines targeted delivery with light-triggered drug release and intracellular imaging (Fu *et al.,* 2019). A compelling example of these strategies in practice is the development of PolyDots—hybrid nanomicelles that merge the properties of polymeric nanoparticles and micelles. PolyDots have shown promise in brain tumor models by enabling dual-drug encapsulation, sustained intratumoral release, BBB penetration, and integrated imaging for real-time therapeutic monitoring (Xu *et al.,* 2015).

These principles have been successfully applied to highly challenging conditions such as glioblastoma multiforme (GBM) and neurodegenerative diseases. GBM, which features a partially compromised blood–tumor barrier (BTB), poses unique obstacles due to its location and biological heterogeneity. Approaches like viral vector-assisted nanoparticle delivery, stem cell–nanoparticle hybrids for tumor targeting, and MRI-guided magnetic targeting with iron oxide particles have demonstrated notable efficacy (Chaudhuri & Straubinger, 2019). In neurodegenerative diseases such as Alzheimer's and Parkinson's, nanoparticles offer sustained drug release to reduce the frequency of dosing, anti-inflammatory delivery to modulate microglial activation, and gene editing strategies such as CRISPR encased in biodegradable carriers. Lipid-based nanoparticles, including liposomes and solid lipid nanoparticles, have shown high CNS targeting efficiency with reduced systemic toxicity, as highlighted by Alaa Alqudah *et al.,* (2024).



Graph 1: Nanotechnology Strategies to Overcome Biological Barriers

3. Role of Nanotechnology in Cancer Therapy:

3.1. Nanocarriers for Chemotherapy and Combination Therapies

Nanotechnology has revolutionized cancer treatment by enabling the development of highly specific, targeted, and multifunctional delivery systems known as nanocarriers. These nanoscale vehicles are engineered to deliver chemotherapeutic agents with enhanced efficacy and reduced side effects. A wide array of nanocarrier systems—such as liposomes, lipid nanoparticles (LNPs), micelles, nanospheres, nanocapsules, and dendrimers—have been extensively studied for their applications in both monotherapy and combination therapy in oncology.

Liposomes, spherical vesicles composed of phospholipid bilayers, can encapsulate both hydrophilic and hydrophobic drugs. Their biocompatibility and ability to enhance drug solubility have made them one of the most clinically established nanocarriers in cancer chemotherapy. For instance, liposomal formulations like Doxil® have significantly reduced the cardiotoxicity of doxorubicin while maintaining its therapeutic potential. In parallel, lipid nanoparticles represent an advanced platform characterized by structural stability and versatility in loading hydrophobic drugs, RNA-based therapeutics, or drug combinations. Their architecture enhances circulation time and tumor accumulation, vital for both passive and active targeting strategies (Fang *et al.,* 2022; Qamar *et al.,* 2023).

Micelles, another important nanocarrier type, are self-assembling amphiphilic structures with a hydrophobic core and a hydrophilic shell. They are particularly well-suited for delivering poorly soluble drugs and shielding them from degradation during systemic circulation. These carriers can also be engineered to respond to stimuli such as pH, temperature, or redox gradients present in tumor microenvironments. Such stimuli-responsiveness enables precise drug release and minimizes systemic toxicity (Chen *et al.,* 2020). A notable advantage of micelles is their amenability to surface functionalization with targeting ligands and additional therapeutic agents. Dual-loaded micellar systems, combining chemotherapy with photodynamic therapy, have shown synergistic anticancer effects in preclinical studies (Yang *et al.,* 2021).

Polymeric nanocarriers, which include nanospheres and nanocapsules, offer another promising strategy. Nanospheres are solid matrices in which drugs are uniformly dispersed, whereas nanocapsules feature a polymeric shell that encloses a liquid or semi-solid drug core. Both types offer controlled drug release, high drug-loading efficiency, and stability in biological environments (Hu *et al.,* 2021). Innovations in stimuli-responsive nanocapsules, such as metal-organic framework (MOF)-based hybrids, are especially promising for combination therapy. For example, co-encapsulation of cisplatin and doxorubicin in pH-responsive MOF@polymer nanocarriers has shown improved drug accumulation in resistant tumor cells and enhanced therapeutic outcomes in vivo.

Dendrimers are highly branched, tree-like macromolecules composed of a central core, internal branches, and multiple surface functional groups. Their well-defined and tunable structure enables precise control over molecular size, shape, and surface properties. These attributes make dendrimers highly effective platforms for co-delivery of chemotherapeutics, imaging agents, and targeting ligands. Emerging research underscores their potential in combination therapies aimed at synchronously delivering drugs and immunomodulators or imaging compounds. Their extensive surface area supports the attachment of multiple therapeutic moieties, enabling coordinated drug release and enhanced treatment efficacy (Cao *et al.,* 2024).



Figure 4: Nanocarriers for Enhanced Chemotherapy and Combination Therapies"

This figure presents schematic illustrations of five major nanocarrier types employed in cancer therapy. Liposomes (a) are bilayer vesicles capable of encapsulating both hydrophilic and hydrophobic drugs, enabling targeted delivery with reduced systemic toxicity. Lipid nanoparticles (b) are solid lipid-based systems designed to offer high drug stability and controlled release profiles. Micelles (c) are self-assembled amphiphilic structures particularly effective for solubilizing poorly water-soluble drugs and protecting them during systemic circulation. Polymeric nanocarriers, including nanospheres and nanocapsules (d), provide matrix-based or core-shell drug entrapment mechanisms that facilitate sustained and controlled drug release. Finally, dendrimers (e) are highly branched, tree-like macromolecules with tunable surface functionalities, making them ideal for multifunctional delivery platforms, including the co-delivery of therapeutic and diagnostic agents.

3.2. **Nanotheranostics: Simultaneous Imaging and Treatment**

The convergence of diagnostics and therapeutics into a single nanoparticle platform, known as nanotheranostics, has emerged as a transformative strategy in cancer management. These multifunctional nanosystems enable simultaneous disease visualization and treatment, allowing real-time monitoring of therapeutic efficacy and enhancing precision in cancer care. Traditional cancer treatments often suffer from poor targeting and delayed feedback, but nanotheranostics overcomes these challenges by facilitating the localization of tumors, enabling tailored drug delivery, and allowing dynamic adjustment of treatment protocols based on imaging responses.

Nanotheranostics is supported by several nanosystem platforms, including metallic nanoparticles such as gold and iron oxide, polymeric nanoparticles, and lipid-based carriers like solid lipid nanoparticles (SLNs), micelles, nanostructured lipid carriers (NLCs), and liposomes. These carriers are designed to perform two key roles simultaneously: therapy and imaging. The therapeutic function includes the delivery of chemotherapeutic agents, nucleic acids, proteins or peptides, and stimuli-responsive molecules, while the imaging function is achieved through the integration of fluorescent dyes, quantum dots, iron or gold nanoparticles, and gadolinium-based contrast agents. This dual functionality ensures precise targeting and continuous imaging feedback, enabling clinicians to monitor disease progression and adjust treatment regimens in real time.

The therapeutic payloads incorporated into nanotheranostic systems are diverse, including cytotoxic drugs such as doxorubicin and paclitaxel, nucleic acids like siRNA and miRNA, and therapeutic proteins or peptides. More recent advancements have introduced stimuli-responsive molecules that trigger drug release in response to tumor-specific conditions such as acidic pH, elevated temperature, or specific enzymatic activity (Gupta *et al.,* 2024). Polymeric nanoparticles and liposomes are capable of encapsulating multiple agents, allowing for combination therapies that minimize drug resistance and enhance therapeutic efficacy. Similarly, micelles and NLCs, with their amphiphilic architecture, improve the solubility and circulation time of hydrophobic drugs (Parveen *et al.,* 2024).

From a diagnostic perspective, nanotheranostic platforms integrate a range of imaging agents tailored for various modalities such as magnetic resonance imaging (MRI), positron emission tomography (PET), computed tomography (CT), fluorescence imaging, and photoacoustic imaging. These agents allow real-time tracking of nanoparticle distribution, tumor targeting, and drug release. Commonly used imaging components include quantum dots for multiplexed fluorescence imaging, iron oxide nanoparticles for MRI, gold nanoparticles for optical contrast and CT enhancement, and gadolinium-based agents to boost MRI sensitivity. These imaging agents are often conjugated to the nanoparticle surface, enabling precise tumor localization without requiring invasive procedures (Dennahy *et al.,* 2022).

One of the major strengths of nanotheranostics lies in its targeting capability, which is achieved through both passive and active mechanisms. Passive targeting exploits the enhanced permeability and retention (EPR) effect, which allows nanoparticles to preferentially accumulate in tumor tissues due to their leaky vasculature. Active targeting, on the other hand, involves surface modification of nanoparticles with ligands such as antibodies, peptides, or small molecules that bind specifically to tumor-associated receptors. For example, anti-EpCAM-conjugated upconversion nanoparticles have been successfully used to target pancreatic cancer stem cells while enabling dual-modality imaging and photodynamic therapy (Han *et al.,* 2021).

Recent studies have demonstrated the effective integration of therapeutic and diagnostic functions in single nanoparticle platforms, showing promise for clinical application. Hybrid CaO_2–Fe_3O_4 nanocomposites have been developed to deliver hydrogen peroxide for chemodynamic therapy while simultaneously enabling magnetic and near-infrared fluorescence imaging in vivo (Han *et al.,* 2019). Likewise, gold nanoconjugates loaded with both chemotherapeutic agents and imaging dyes have shown tumor suppression in preclinical models while allowing continuous visualization of drug delivery (Katifelis & Gazouli, 2021). In another example, polymeric micelles with pH-sensitive drug release and fluorescence tags demonstrated both tumor-specific drug release and imaging in breast and liver cancer models (Naser *et al.,* 2024). These examples illustrate the capacity of nanotheranostics to merge real-time imaging with

precisely controlled therapy, enabling a more refined and effective approach to cancer treatment.

According to Figure 5, which provides a functional overview of nanotheranostic systems, the schematic effectively illustrates their dual functionality. The top section of the figure outlines various types of nanosystems, including metallic, polymeric, and lipid-based structures such as SLNs, micelles, NLCs, and liposomes, showcasing the structural diversity of these platforms. The left portion of the diagram highlights the therapeutic agents incorporated into these systems, while the right side lists the diagnostic tools embedded in the same nanoparticles. The figure's bottom section unifies these components under the concept of cancer nanotheranostics, reinforcing the idea of a co-functionalized nanomedicine system capable of detection and treatment in a single construct.

Despite the immense promise of nanotheranostics, several challenges remain. Concerns regarding toxicity and biocompatibility, particularly with heavy-metal-based nanoparticles like quantum dots and gold particles, require further investigation (Paliwal *et al.,* 2020). Clinical translation also faces obstacles, as many successful preclinical studies have yet to advance to human trials due to issues with scalability, manufacturing reproducibility, and complex regulatory approval processes (Ain, 2019). Additionally, tumor heterogeneity—manifested through varying expression levels of surface markers and differences in tumor microenvironments—can compromise targeting accuracy and imaging fidelity. To address these issues, ongoing research is focused on developing biodegradable, responsive, and patient-specific nanotheranostic platforms.

Looking ahead, the future of cancer treatment is clearly leaning toward personalized, image-guided therapy, with nanotheranostics poised to play a central role. Innovative developments include smart nanomaterials capable of altering their shape, charge, or function in response to specific biological stimuli, and multimodal systems that integrate chemotherapy, phototherapy, immunotherapy, and radiotherapy within a single platform. Furthermore, artificial intelligence is increasingly being incorporated into these systems to optimize nanoparticle design and function based on real-time imaging feedback. With advances in biocompatibility, targeted delivery, and interdisciplinary collaboration, nanotheranostics is expected to lead the transition from reactive to precision oncology, bringing about a new era of highly individualized and effective cancer care (Dash *et al.,* 2024).



Figure 5: Nanotheranostics for Simultaneous Imaging and Cancer Therapy.

This schematic illustrates how multifunctional nanoparticles—such as polymeric, solid lipid, micelles, nanostructured lipid carriers, and liposomes—co-deliver therapeutic agents (e.g., chemotherapeutics, nucleic acids, peptides) while enabling a range of imaging modalities like fluorescence, MRI, quantum dots, iron oxide, and gold-based agents.

4.3 Personalized Oncology: Tumor-Specific Nano-Strategies

Personalized oncology has ushered in a new era of cancer treatment, shifting away from the traditional "one-size-fits-all" paradigm toward therapies that are tailored to the molecular and genetic profiles of individual patients. A critical enabler of this transformation is nanotechnology, particularly the use of tumor-specific nanocarriers designed to exploit the unique biological features of each patient's tumor. These nanocarriers are frequently combined with biomarker-guided delivery systems, ensuring highly precise treatment with minimal off-target toxicity and significantly improved therapeutic outcomes.

Nanocarriers for personalized oncology are organized into three interconnected functional components: the polymeric vector, the therapeutic cargo, and MRI contrast agents. The polymeric vector includes advanced nanoparticle platforms such as micelles, dendrimers, nanocapsules, and polymersomes, each optimized for site-specific delivery. The therapeutic cargo comprises cytotoxic agents like doxorubicin, paclitaxel, and natural compounds such as curcumin, chosen according to tumor genomics and drug sensitivity profiles. MRI contrast agents—such as superparamagnetic iron oxide nanoparticles (SPIONs), gadolinium-based compounds, and chemical exchange saturation transfer (CEST) agents—enable real-time visualization of the therapeutic process. Together, these elements exemplify the theranostic principle: merging therapy and diagnostics within a single, adaptive system for individualized cancer care.

Tumor-specific nanocarriers are engineered to operate via either passive or active targeting strategies. Passive targeting leverages the Enhanced Permeability and Retention (EPR) effect, allowing nanoparticles to accumulate preferentially in tumor tissues due to their leaky vasculature. Active targeting, by contrast, involves functionalizing the nanoparticle surface with ligands such as antibodies, peptides, or aptamers that selectively bind to overexpressed receptors on cancer cells. Polymeric nanoparticles, dendrimers, micelles, and liposomes serve as the core platforms for this approach, and recent innovations have focused on developing stimuli-responsive carriers that release their therapeutic payload in response to specific tumor microenvironmental cues such as pH shifts, redox gradients, or enzymatic activity (Eskandar, 2025).

A key advancement in this domain has been the integration of nanocarriers with biomarker-guided therapy. Biomarkers like HER2, EGFR, and PSMA are increasingly being utilized to design nanocarriers that selectively bind to malignant cells while sparing healthy tissue. For instance, aptamer-based targeting systems have shown great promise in prostate cancer therapy. These short, synthetic nucleic acid sequences exhibit high affinity for tumor-specific biomarkers and can be conjugated to nanocarriers to enhance cellular uptake and reduce immunogenicity (Shahrukh *et al.,* 2023).

Therapeutic payloads in these nano-strategies are tailored to maximize efficacy and minimize toxicity. Cytotoxic drugs such as doxorubicin, 5-fluorouracil, and paclitaxel remain foundational, but natural agents like curcumin have gained traction due to their ability to modulate multiple signaling pathways simultaneously. Moreover, nanocarriers are being developed to deliver nucleic acids—including siRNA and CRISPR-Cas9 constructs—for gene editing applications. These payloads are encapsulated or conjugated in ways that allow for sustained, localized release at the tumor site, thereby enhancing therapeutic indices. Multi-drug nanocarriers are also under investigation to overcome multidrug resistance and achieve synergistic therapeutic effects (Chen *et al.,* 2023).

MRI-guided nanotherapy represents a breakthrough in real-time treatment monitoring. Nanocarriers embedded with imaging agents like SPIONs for T2-weighted imaging or gadolinium complexes for T1-weighted imaging enable continuous visualization of drug biodistribution and treatment efficacy. This theranostic integration allows for dynamic dose adjustment and optimized therapeutic response (Hristova-Panusheva *et al.,* 2024). Additionally, CEST agents and ^19F-labeled nanoparticles are being explored to quantitatively track drug delivery events, further enhancing the personalization of cancer care.

The integration of nanomedicine with 'omics' technologies—genomics, proteomics, metabolomics, and transcriptomics—has enabled unprecedented personalization. Nanocarriers can now be engineered to recognize specific genomic or proteomic signatures, allowing for custom-tailored payloads and targeting strategies (Ahmad & Mohammad, 2021). Advanced computational tools, including artificial intelligence and machine learning, are increasingly applied to screen nanoparticle designs against large omics datasets. These technologies enable in silico optimization of nanoparticle behavior and formulation before advancing to clinical development (Boehnke & Hammond, 2021).

Despite the promise of personalized nanomedicine, several biological and physiological barriers remain. The formation of a protein corona on the nanoparticle surface can hinder targeting efficacy, while tumor heterogeneity complicates receptor-specific delivery. Furthermore, intracellular delivery—especially for nucleic acid therapies—remains a challenge. To address these issues, research is focusing on strategies such as PEGylation, biomimetic coatings, and multifunctional core-shell nanoparticle architectures to enhance circulation time, avoid immune detection, and facilitate endosomal escape (López-Estévez *et al.,* 2023).

Translational advances are also being realized as personalized nanocarriers move into clinical evaluation. Notable examples include Doxil®, a PEGylated liposomal doxorubicin approved for ovarian and breast cancer, and Abraxane®, an albumin-bound paclitaxel formulation that enhances tumor penetration. More recent innovations include PEG-b-PLA micelles functionalized with HER2-targeting ligands for breast cancer treatment (Bennani *et al.,* 2024). These platforms are being evaluated in conjunction with imaging modalities such as MRI and PET-CT, alongside biomarker analysis, to enable adaptive therapy strategies in real time.

Nonetheless, significant challenges persist. Regulatory pathways for multi-component

nanomedicines are complex and often poorly defined. Clinical-grade scale-up requires highly reproducible and scalable manufacturing processes. Long-term safety, biodegradability, and toxicity profiles must be rigorously evaluated. Moreover, the cost and accessibility of these sophisticated systems pose hurdles in global healthcare environments. Looking forward, the field aims to develop universal, modular nanoplatforms capable of responsive drug delivery, integrated imaging, and bioinformatics support to address cancer's inherent heterogeneity more effectively.

In conclusion, personalized oncology empowered by tumor-specific nanocarriers represents a frontier in precision cancer therapy. By seamlessly integrating targeted drug delivery, biomarker profiling, real-time imaging, and data-driven optimization, nanomedicine is enabling truly individualized treatment regimens. This holistic approach brings together polymeric vectors, precision-selected therapeutic agents, and MRI-based monitoring into a cohesive, patient-centric strategy. Continued interdisciplinary research across nanotechnology, bioinformatics, and clinical oncology will be vital for translating these promising platforms from bench to bedside.

4. Advances in Nano-Enabled Vaccinology

4.1. Nanoparticles as Antigen Carriers and Immune Adjuvants

The development of effective vaccines hinges on the efficient delivery of antigens to the immune system and the enhancement of immunogenicity through adjuvants. In recent years, nanoparticles (NPs) have emerged as powerful tools in this context, serving dual roles as both antigen carriers and immune-stimulating adjuvants. Their tunable physicochemical properties—including size, shape, surface charge, and composition—allow for precise control over antigen loading, delivery, and immune modulation, making them a cornerstone of next-generation vaccinology.

Nanoparticles are particularly effective at enhancing antigen uptake and processing by antigen-presenting cells (APCs) such as dendritic cells and macrophages. Their nanoscale size, typically ranging from 10 to 500 nm, mimics the dimensions of natural pathogens and facilitates efficient transport to lymph nodes, key sites of immune activation (Wang *et al.,* 2019). In addition to their optimal size, many nanoparticles can be surface-functionalized, allowing the stable conjugation or encapsulation of antigens and immunostimulatory molecules in bioavailable forms. For example, poly(amino acid) nanoparticles like amphiphilic poly(glutamic acid) have been shown to be pH-responsive, enhancing endolysosomal escape and cross-presentation. This leads to elevated MHC class I expression and cytokine secretion, thereby boosting T cell activation in murine models (Zhang *et al.,* 2023).

Importantly, nanoparticles often exhibit intrinsic adjuvant properties, functioning not only as delivery vehicles but also as immunostimulants. Poly-γ-glutamic acid (γ-PGA) nanoparticles, for instance, enhance both antigen delivery and immune activation by promoting cytokine release and T cell responses (Mohammadzadeh *et al.,* 2023). In another study, PLGA (poly(lactic-co-glycolic acid)) nanoparticles loaded with the EsxB antigen triggered significantly higher interleukin levels than soluble antigen alone, confirming their standalone adjuvant capacity (Zhu *et al.,* 2023). Gold nanoparticles (AuNPs) have similarly demonstrated strong self-adjuvanticity, facilitating efficient macrophage uptake and promoting antigen presentation via MHC class II pathways. Vaccination with AuNP–antigen conjugates resulted in significantly higher IgG titers compared to conventional formulations (Lin *et al.,* 2022).

Nanoparticles can also be tailored to elicit specific immune response types. Cationic lipid-based systems incorporating Toll-like receptor agonists, for instance, have shown the capacity to induce a Th1-skewed immune profile, which is essential for combating intracellular pathogens like *Bordetella pertussis* (Aibani *et al.,* 2022). Additionally, chitosan-modified nanoparticles have enhanced mucosal vaccine efficacy by improving mucoadhesion, facilitating antigen uptake, and increasing mucosal IgA production. These systems effectively stimulate both systemic IgG and mucosal sIgA responses, supporting a comprehensive protective effect (Sinani *et al.,* 2019).

The versatility of nanoparticle platforms is further demonstrated by their ability to deliver a range of antigen types—including proteins, peptides, and polysaccharides—across various disease models, such as cancer, viral infections, and bacterial diseases. For example, flagellin-based ring-shaped nanoparticles exploit Toll-like receptor 5 activation to promote antigen presentation and induce robust adaptive immune responses (Côté-Cyr *et al.,* 2022). Some advanced nanoparticle platforms also allow for real-time tracking of antigen and adjuvant delivery using imaging techniques. This has proven especially useful in cancer vaccine development, where co-delivery systems incorporating CpG oligodeoxynucleotides and antigens in a single traceable formulation have enhanced precision and therapeutic efficacy (Dong *et al.,* 2019).

The field is rapidly evolving with novel developments at the intersection of material science and immunology. Virus-like nanoparticles (VLPs), which structurally mimic native pathogens, have demonstrated exceptional potential in enhancing lymph node retention and promoting germinal center formation, leading to prolonged and more effective antibody responses (Zhang *et al.,* 2024). Moreover, emerging studies suggest that some nanoparticles—such as silver and silica—can act not only as carriers but also as antigens themselves,

inducing significant antibody responses without additional adjuvants (Li *et al.,* 2021). These findings highlight the multifaceted role of nanoparticles in vaccine design and point to a future where immunogenic nanomaterials may revolutionize both preventive and therapeutic immunization strategies.

4.2. mRNA Vaccines and Lipid Nanoparticles (LNPs)

Messenger RNA (mRNA) vaccines represent a groundbreaking advancement in modern vaccinology, offering rapid, adaptable, and scalable solutions for combating infectious diseases and various forms of cancer. Central to the success of these vaccines is the use of lipid nanoparticles (LNPs), which protect mRNA molecules from enzymatic degradation, enhance cellular uptake, and ensure their successful release into the cytoplasm where translation into immunogenic proteins occurs. These nanoscale delivery vehicles enable efficient expression of antigenic proteins, triggering robust immune responses and paving the way for next-generation vaccine platforms.

LNPs are typically composed of four main components: an ionizable lipid to facilitate endosomal escape, helper lipids such as DSPC for structural support, cholesterol for membrane fluidity, and polyethylene glycol (PEG)-lipids that confer colloidal stability. This composition allows the LNPs to encapsulate mRNA and deliver it efficiently into target cells. The historic deployment of mRNA-LNP vaccines during the COVID-19 pandemic marked a significant milestone for this technology. Both the Pfizer-BioNTech and Moderna vaccines utilized nucleoside-modified mRNA encased in LNPs, demonstrating outstanding efficacy and safety profiles in large-scale global populations (Hou *et al.,* 2021). These LNPs facilitate antigen presentation through both MHC class I and II pathways, stimulating robust humoral and cellular immunity.

The intracellular mechanism of LNPs is critical to their therapeutic effect. Upon endocytosis, the acidic environment within endosomes protonates the ionizable lipids in the LNPs, leading to fusion with endosomal membranes and release of mRNA into the cytosol (Trollmann & Böckmann, 2022). This pH-sensitive behavior not only ensures the preservation of mRNA function but also minimizes unintended immune activation. Lipid composition plays a vital role in this process, as variations in the type and ratio of lipid components can influence immunogenicity, toxicity, and overall delivery efficiency (Tanaka *et al.,* 2022).

Recent advances in mRNA-LNP engineering have sought to further enhance stability, reduce inflammation, and improve tissue-specific delivery. For example, vitamin B5-derived ionizable lipids have been incorporated to reduce systemic toxicity and direct delivery to lymphoid tissues—an essential target for initiating immune responses (Yoo *et al.,* 2024). Other studies have explored biodegradable LNP formulations, such as G-LNPs composed of poly(guanidine thioctic acid), which have demonstrated superior mRNA translation efficiency, reduced oxidative stress, and heightened antitumor activity (Yang *et al.,* 2024). Furthermore, new adjuvant lipidoids are being designed to enhance innate immune stimulation, particularly through Toll-like receptor (TLR) activation, to induce potent Th1-biased responses necessary for both antiviral and anticancer immunity (Han *et al.,* 2023).

Beyond COVID-19, mRNA-LNP platforms have demonstrated clinical potential across a wide range of infectious and non-infectious diseases. Studies are ongoing for vaccines against influenza, respiratory syncytial virus (RSV), Zika virus, HIV, and tuberculosis. In oncology, mRNA-LNPs are facilitating the development of personalized neoantigen vaccines for cancers such as melanoma and other solid tumors (Jacob *et al.,* 2024). Additionally, LNPs are being explored for protein replacement therapies and gene editing applications. One promising example includes targeted delivery of mRNA to hepatocytes for the expression of clotting factors in hemophilia models (Wang *et al.,* 2021).

Despite their promise, safety remains a critical consideration. Most mRNA-LNP vaccines have been associated with mild to moderate adverse events, including local pain, fever, and short-term inflammation. Strategies to mitigate these effects include the design of disulfide-cleavable and pH-activated lipids that retain immunogenicity while minimizing proinflammatory cytokine release (Kawai *et al.,* 2024). Additionally, replacing traditional ionizable lipids with less immunogenic analogs has shown promise in reducing systemic reactions without compromising vaccine efficacy (Zhang *et al.,* 2024).

Nevertheless, several challenges persist in the advancement and global deployment of mRNA-LNP technology. Cold-chain storage requirements pose significant limitations for distribution in resource-constrained regions, while refining tissue-targeting accuracy remains essential to avoid off-target effects. Furthermore, large-scale, GMP-compliant manufacturing methods must be optimized to meet growing global demand. Fortunately, ongoing interdisciplinary research is addressing these gaps. Innovations such as room-temperature-stable LNPs and lyophilized mRNA vaccine formulations are in development, which could dramatically improve global accessibility and equity in vaccine distribution (Wu *et al.,* 2024).

4.3. Applications in Infectious Diseases and Emerging Pathogens

The emergence of mRNA and nanoparticle-based vaccines has revolutionized contemporary immunization strategies, particularly in the context of infectious diseases and emerging global health threats.

Their success during the COVID-19 pandemic offered indisputable proof-of-concept for the rapid development, manufacturing, and deployment of highly effective and safe vaccines in the face of unprecedented crises. These versatile platforms continue to evolve and expand into broader applications, addressing viral, bacterial, and zoonotic pathogens with pandemic potential.

The most notable application of mRNA-nanoparticle technology was seen during the COVID-19 pandemic, where the Pfizer-BioNTech and Moderna vaccines used lipid nanoparticles (LNPs) to deliver nucleoside-modified mRNA encoding the SARS-CoV-2 spike protein. These vaccines demonstrated efficacy levels exceeding 90% in preventing symptomatic infection and were developed, tested, and approved in under a year—an achievement made possible by the modularity of mRNA platforms and the efficiency of nanoparticle-mediated delivery (Chaudhary *et al.,* 2021). LNPs protect fragile mRNA from enzymatic degradation, enable efficient cellular uptake, promote endosomal escape, and ensure cytosolic translation into antigenic proteins, making them ideal vectors for rapid-response vaccination efforts (Asr *et al.,* 2023).

Building on the success of COVID-19 vaccines, numerous mRNA-LNP candidates are now under development for a wide range of infectious agents, including influenza, Zika virus, HIV, cytomegalovirus, and respiratory syncytial virus (RSV). These efforts reflect the adaptability of mRNA platforms in encoding diverse antigenic structures and their potential to manage seasonal, endemic, and pandemic threats (Pilkington *et al.,* 2021). Notably, an mRNA-LNP vaccine targeting porcine deltacoronavirus has shown higher neutralizing antibody titers and superior protection compared to traditional inactivated vaccines, highlighting its value for preventing zoonotic spillover events (Li *et al.,* 2024).

One of the key strengths of mRNA vaccine technology is its capacity to swiftly adapt to pathogen diversity and mutation. Unlike conventional platforms, mRNA sequences can be rapidly re-engineered to match emerging variants without altering the core manufacturing process. This agility is especially valuable for combating rapidly evolving viruses such as influenza and HIV, where traditional vaccines often lag behind circulating strains (Chen *et al.,* 2023). Furthermore, mRNA constructs can be designed to encode multiple antigens or epitopes, enabling multivalent vaccines that provide broader protection across different serotypes or co-circulating pathogens.

In addressing the threat of emerging zoonotic and vector-borne diseases, mRNA-LNP platforms are gaining recognition as effective front-line technologies. Diseases such as Nipah virus, Ebola, and dengue are of particular concern due to their epidemic potential and lack of licensed vaccines. mRNA-LNPs offer the advantage of rapid design, scalable production, and compatibility with cold-chain storage, making them suitable for urgent response scenarios. In preclinical animal models, mRNA vaccines targeting emerging influenza strains and hemorrhagic fever viruses have demonstrated the ability to elicit cross-reactive T cell and antibody responses (Yu *et al.,* 2023).

To address current limitations such as short-lived protein expression, researchers are exploring innovative RNA formats like self-amplifying RNA (saRNA) and circular RNA (circRNA). These constructs can prolong antigen expression and reduce the required dosage, thereby improving vaccine efficacy and accessibility, particularly in low-resource regions where distribution is challenging (Zhou *et al.,* 2023). In parallel, biologically derived nanocarriers such as virus-like particles (VLPs) and outer membrane vesicles (OMVs) are emerging as alternative delivery vectors. These structures inherently mimic the architecture of pathogens, often exhibiting natural adjuvanticity and biocompatibility, which allows them to elicit strong immune responses without the need for additional adjuvants (Curley & Putnam, 2022). For instance, OMVs engineered to express heterologous antigens have shown significant promise in preclinical models for diseases like meningitis and gonorrhea.

Despite these advances, several key challenges remain in the broad implementation of mRNA-nanoparticle vaccines against infectious diseases. Cold-chain logistics present a significant obstacle, as current LNP formulations often require storage at ultra-low temperatures, limiting distribution in lower-income regions. Efforts are underway to develop thermostable and lyophilized vaccine formulations to overcome this barrier (Chaudhary *et al.,* 2021). Moreover, large-scale GMP-compliant manufacturing remains technically demanding and costly. Another concern is the duration of immunity; while mRNA vaccines are highly effective in the short term, their long-term protective effects—particularly against chronic or latent infections—are still under investigation. Lastly, global equity and access to these advanced vaccines continue to pose ethical and logistical challenges, especially for low- and middle-income countries.

Nevertheless, ongoing research and technological innovation are addressing these concerns. Improvements in nanoparticle design, RNA engineering, and alternative delivery routes such as intranasal or oral formulations hold great promise for broadening the reach and durability of these vaccines (Prakash, 2023). With continued progress, mRNA-nanoparticle platforms are poised to become a cornerstone of global preparedness and response strategies for infectious diseases and future pandemics.

5. Nanoscale Biosensors and Diagnostics

5.1. Quantum Dots and Nanoshells for Bioimaging

Recent breakthroughs in nanotechnology have transformed biomedical imaging, with quantum dots (QDs) and gold nanoshells emerging as two of the most promising nanomaterials for enhancing imaging resolution, sensitivity, and multiplexing capability. These nanoscale systems interact with light in highly tunable ways, opening new possibilities for tracking biological events, detecting early disease markers, and guiding targeted therapeutic interventions.

Quantum dots are semiconductor nanocrystals typically 2–10 nm in diameter, prized for their extraordinary optical characteristics. Their size-tunable fluorescence, broad excitation spectra, narrow emission bands, and superior photostability make them ideal for use as fluorescent probes. Unlike conventional dyes, QDs resist photobleaching, allowing prolonged imaging in live and fixed biological systems (Wagner *et al.,* 2019). Their emission properties can be precisely tailored by adjusting the core and shell composition—such as cadmium selenide/zinc sulfide (CdSe/ZnS) structures—which emit bright, stable light in the visible range. These features enable multiplexed imaging, where multiple targets can be detected simultaneously with minimal spectral overlap (Fan & Yi, 2024). In applications such as cancer diagnostics, QDs conjugated with tumor-specific antibodies like anti-HER2 have been used for high-resolution fluorescence imaging of breast cancer cells, enabling single-cell analysis and molecular profiling (Aguilar *et al.,* 2020).

Gold nanoshells, composed of a dielectric core such as silica surrounded by a thin gold layer, offer a complementary optical modality. Their unique plasmonic properties allow precise control over light absorption and scattering across visible and near-infrared (NIR) wavelengths. The NIR region is particularly suitable for deep-tissue imaging, as it minimizes light absorption by biological tissues (Prasanna *et al.,* 2019). These particles serve as contrast agents in optical coherence tomography and photoacoustic imaging, and can also be employed for photothermal therapy. When accumulated in tumors, gold nanoshells convert NIR light into heat, effectively ablating cancerous cells. Their high biocompatibility and surface modifiability enable attachment to targeting ligands such as DNA, peptides, or antibodies, which enhances selectivity for disease markers (Kulakovich *et al.,* 2022).

Recent research has explored hybrid nanostructures that combine the benefits of quantum dots and gold nanoparticles. These constructs leverage plasmon-enhanced fluorescence, where the proximity of QDs to gold particles amplifies their emission intensity, resulting in significantly improved biosensing sensitivity (Devi *et al.,* 2024). Illustrates such hybrid systems constructed using DNA origami scaffolds, which position QDs and gold nanoparticles at nanometer precision. The diagram shows configurations with planar DNA templates assembling QDs and AuNPs in geometrically controlled arrays, optimizing them for multiplexed detection and cellular imaging. A transmission electron microscopy (TEM) image in the lower panel confirms accurate assembly of these nanostructures, validating their potential for applications such as live-cell tracking, molecular diagnostics, and signal amplification.

Despite their promise, the translation of QDs and nanoshells to clinical practice faces important biocompatibility and safety hurdles. Traditional QDs, especially those containing heavy metals like cadmium, raise toxicity concerns due to possible metal ion leakage and accumulation in organs such as the liver and kidneys (Reshma & Mohanan, 2019). In response, non-toxic alternatives such as carbon dots, indium phosphide QDs, and graphene quantum dots (GQDs) are being developed (Ali *et al.,* 2021). Gold nanoshells, on the other hand, are widely regarded as safe and chemically inert. Their surfaces can be functionalized with polyethylene glycol (PEG) to prolong circulation time and reduce immune system recognition, while maintaining optical performance in biological environments.

The diagnostic and therapeutic applications of QDs and nanoshells span multiple fields. In oncology, these nanomaterials are widely used for cancer detection, real-time intraoperative guidance, and sentinel lymph node mapping. Fluorescent QDs help delineate tumor margins, while gold nanoshells enable thermal imaging and targeted ablation (Grimaldi *et al.,* 2022). In infectious disease monitoring, QDs functionalized with pathogen-specific ligands offer rapid detection of viruses and bacteria, often surpassing traditional PCR or ELISA in terms of speed and multiplexing. For genetic screening, QDs linked with nucleic acid probes enable precise fluorescent detection of single nucleotide polymorphisms, gene mutations, or microRNAs, contributing to personalized medical diagnostics (Sotnikov *et al.,* 2020).

Looking ahead, several challenges must be addressed to fully integrate these nanomaterials into clinical workflows. Key issues include mitigating toxicity through biodegradable QD formulations, scaling up production methods for consistent quality and affordability, and standardizing protocols for imaging and bioclearance. However, the combination of QDs and gold nanoshells—especially in synergistic hybrid platforms like those —holds transformative potential. These “intelligent diagnostics” offer real-time, non-invasive imaging capabilities with unparalleled precision, setting the stage for more effective disease monitoring and targeted intervention strategies in personalized medicine.

5.2. Lab-on-a-Chip and Point-of-Care Nanodiagnostics

The integration of nanotechnology and microfluidics into lab-on-a-chip (LOC) platforms marks a transformative era in diagnostic science. These miniaturized systems combine the analytical capabilities of full-scale laboratories with the compactness and portability required for point-of-care (POC) diagnostics. By embedding nanoparticles and biosensors within microfluidic channels, LOC devices enable rapid, cost-effective, and highly sensitive detection of diseases. Their decentralized nature makes them especially valuable in resource-limited and remote settings where access to centralized laboratories is restricted.

Central to the functionality of LOC devices are nanomaterials such as magnetic nanoparticles (MNPs), gold nanoparticles (AuNPs), and carbon-based nanostructures. These materials possess unique optical, magnetic, and catalytic properties that enhance sample processing, signal amplification, and biospecific targeting. Nanomaterials are instrumental in various diagnostic stages, including sample preparation, biomarker detection, and signal transduction. Their effectiveness has been well documented across nucleic acid- and antibody-based detection platforms, offering improved accuracy and integration potential for infectious disease diagnostics (Markandan *et al.,* 2022).

The mechanism of a typical nanodiagnostic LOC device is multifaceted and integrates all key steps—sample introduction, biomarker extraction, amplification, and detection—onto a single chip. As illustrated, one example involves magnetic nanoparticles used for the targeted isolation of bacteria such as *E. coli*. A fluid sample introduced into the system binds to MNPs, forming complexes that are then magnetically sorted through designated outlets, ensuring high-purity sample isolation. Another system incorporates solid-phase DNA extraction with silica beads and chaotropic salts, followed by loop-mediated isothermal amplification (LAMP) and colorimetric readout via a lateral flow strip. This design enables multiplexed pathogen detection with built-in fluid reservoirs and micro-valves for automated operation. A third example uses an electrochemical aptamer-based sensor (EA-sensor) for the rapid detection of *E. coli* O157:H7 in milk. Here, DNA hybridization and catalytic reactions involving hydrogen peroxide generate a colorimetric signal visible to the naked eye—offering true one-step field-ready diagnostics.

The clinical applications of these technologies span a wide spectrum. During the COVID-19 pandemic, LOC devices integrating gold or platinum nanoparticles proved invaluable for detecting SARS-CoV-2 nucleocapsid proteins at femtogram concentrations, outperforming conventional lateral flow assays (Wu *et al.,* 2022). In food safety, such as detecting bacterial contamination in milk, POC biosensors like the EA-sensor mentioned earlier demonstrate how aptamer-functionalized nanoparticles can ensure accuracy even in complex sample environments. LOC devices have also been employed in genetic and chronic disease diagnosis. For example, hepatitis B virus DNA has been directly detected from blood using MNP-assisted extraction and integrated PCR amplification on-chip, delivering results within 30 minutes (Fang *et al.,* 2022). Furthermore, in oncology, microfluidic chips decorated with nanoparticles have enabled non-invasive detection of cancer biomarkers such as extracellular vesicles and circulating tumor DNA, now entering clinical validation (Mahshid, 2023).

Innovations driving the field forward include multiplexing capabilities that allow simultaneous detection of multiple pathogens or genetic markers on a single chip, digital readouts connected to smartphones or handheld readers, and self-contained cartridge systems that require no operator intervention. Some modern LOC platforms now feature integration with Internet of Things (IoT) technologies and artificial intelligence, enabling cloud connectivity for real-time epidemiological monitoring and decision support (Perinjelil, 2024).

However, significant challenges persist. Manufacturing microfluidic chips with consistent nanoparticle behavior at scale remains a hurdle. Additionally, the high cost of raw materials, particularly noble metals like gold and platinum, adds to fabrication expenses. Regulatory hurdles also impede widespread clinical adoption, as extensive validation, safety profiling, and formal approval processes are required. A further complication is the integration of complex assay steps—such as nucleic acid amplification and optical/electrochemical detection—into a unified, compact, and robust platform.

The future of LOC nanodiagnostics lies in advancing toward thermally stable, disposable cartridges that function in low-resource environments, and in wearable biosensors capable of continuous physiological monitoring via embedded microfluidics. Self-powered devices using capillary-driven or paper-based fluidics could remove the need for external pumps, making diagnostics even more accessible. Emerging technologies also suggest exciting new directions, such as CRISPR-based detection integrated with nanomaterial-enhanced fluorescence for ultra-specific and sensitive diagnostics. As highlighted in recent studies (Chokkareddy *et al.,* 2021; Singh & Yadava, 2020), these innovations will likely make LOC platforms indispensable for monitoring infectious disease outbreaks, enabling early diagnosis of chronic illnesses, and delivering healthcare in a truly decentralized, patient-centric manner.

The schematic illustrates a microfluidic lab-on-a-chip platform featuring embedded nanoparticles—magnetic beads (MPs) for sample

separation and gold nanoparticles (AuNPs)/fluorescent reporters for detection. The device integrates:

a. Sample inlet with magnetic pre-processing and target concentration,
b. DNA extraction and isothermal amplification modules,
c. Detection zones where amplified targets trigger fluorescence or colorimetric signals.

This complete on-chip workflow—from raw sample to read-out—demonstrates high sensitivity, rapid multiplexed pathogen/genetic biomarker detection, and suitability for decentralized, low-resource diagnostic settings.

5.3. Early Detection of Cancer, Infections, and Genetic Disorders

Early detection remains one of the most critical factors in improving survival outcomes and treatment efficacy across both non-communicable and infectious diseases. Nanotechnology-enabled diagnostics, or nanodiagnostics, have brought revolutionary advances to biomedical detection by offering ultra-sensitive, rapid, and highly specific molecular-level analysis. By combining novel nanomaterials with biosensing platforms, these technologies now support real-time, point-of-care (POC) diagnostics across a wide spectrum of diseases, including cancer, emerging infections, and genetic disorders.

The global burden of diseases such as cancer, COVID-19, Zika, Ebola, and genetic conditions like cystic fibrosis or Duchenne muscular dystrophy has spurred the development of early-stage diagnostics that go beyond traditional techniques. While conventional methods like ELISA, PCR, and histopathology are widely used, they often lack sensitivity, require complex instrumentation, or depend on trained personnel. Nanodiagnostics bridge these limitations through miniaturized platforms that employ nanoparticles, nanosensors, and nanoscale imaging agents to detect disease biomarkers at femtomolar or even attomolar concentrations.

In cancer detection, nanotechnology plays a crucial role in overcoming the challenges of diagnosing tumors during early asymptomatic stages. Engineered nanoparticles can target cancer-specific biomarkers such as circulating tumor DNA (ctDNA), exosomes, and proteins like carcinoembryonic antigen (CEA). Quantum dots, gold nanoparticles, and carbon-based nanodots are frequently conjugated with antibodies or aptamers, enabling multimodal detection using optical, electrochemical, and photoacoustic techniques (Gala & Khattar, 2020). In one study, biosensor platforms based on nanostructured surfaces were used to detect CEA at concentrations as low as 1 pg/mL, offering a powerful approach for early colorectal cancer screening (Hariri *et al.,* 2023). For oral cancers, which often present at advanced stages, nanotechnology combined with artificial intelligence has enhanced screening effectiveness. Liu et al. (2023) demonstrated that AI-assisted nanodiagnostic systems significantly improved early detection rates of oral squamous cell carcinoma and oral potentially malignant disorders.

Nanodiagnostics have also shown strong potential in identifying genetic disorders. These diseases often involve single-nucleotide polymorphisms (SNPs) or specific gene deletions that require high-precision detection. CRISPR-Cas-based biosensors, augmented with nanoparticles, have been developed to identify point mutations linked to disorders like sickle-cell anemia and thalassemia. Systems using graphene quantum dots and carbon nanotubes have proven effective in hybridization-based assays, enabling real-time detection of mutated DNA sequences with remarkable specificity (Singh *et al.,* 2021). Moreover, nanopore sequencing technologies enhanced with gold and other conductive nanomaterials have achieved higher base-calling accuracy and increased throughput, contributing to the rapid diagnosis of complex genetic mutations.

For infectious disease detection, nanodiagnostics offer compact, fast-response platforms capable of containing outbreaks and initiating early treatment. During the COVID-19 pandemic, colorimetric biosensors incorporating gold nanoparticles were developed to detect SARS-CoV-2 RNA in under 15 minutes without the need for amplification (Han *et al.,* 2022). Similarly, for tuberculosis, magnetic nanoparticles were used to isolate mycobacterial DNA directly from sputum, expediting LAMP-based detection and increasing diagnostic accuracy (Fang *et al.,* 2022). Integrated lab-on-a-chip platforms using nanomaterials are now capable of detecting pathogens like *E. coli*, *Salmonella*, and Zika virus, combining sample preparation and multiplexed detection on a single microfluidic chip.

One of the most transformative developments is the advent of nanotheranostics—platforms that merge diagnostics with therapy. These systems are capable of identifying tumor-specific biomarkers, triggering therapeutic payload release upon confirmation, and monitoring treatment efficacy in real time (Singh *et al.,* 2024). A compelling example is the use of nanodiamonds, which serve dual functions as both imaging agents and drug carriers. Their inherent fluorescence and biocompatibility make them ideal for tumor imaging and simultaneous therapeutic delivery (Li *et al.,* 2023).

(Conceptually) depicts a nanoparticle-enabled biosensing system for early cancer detection. The illustration shows a microfluidic chip embedded with gold nanoparticles for signal enhancement and functionalized antibody sensors for specificity. Capable of detecting multiple antigens such as CEA, PSA, and HER2, the platform delivers electrochemical or

fluorescence-based readouts, supporting both real-time diagnosis and therapeutic intervention—exemplifying the future of integrated cancer theranostics.

The key advantages of nanodiagnostics are numerous. They achieve extremely high sensitivity and specificity, with detection limits reaching attomolar levels. Their turnaround time is remarkably fast—often delivering results within 10 to 30 minutes. These systems are also capable of multiplexing, allowing for the simultaneous detection of several biomarkers in a single test. Their compact size makes them ideal for field deployment or home-based diagnostics, and they require minimal sample volumes, which is especially important in pediatric and remote healthcare applications.

Nonetheless, several challenges remain before these technologies can reach widespread clinical adoption. Many nanodiagnostic tools are still in preclinical stages, with clinical validation and scalability being significant hurdles. Concerns about biosafety and long-term biocompatibility of some nanoparticles—especially heavy metal-based quantum dots—require thorough investigation. Manufacturing consistency and cost-effectiveness also need to be addressed to ensure broad accessibility. Moreover, regulatory challenges persist due to the absence of standardized validation frameworks for nanodiagnostic devices.

Encouragingly, recent research efforts are focused on developing biodegradable and non-toxic nanomaterials, improving manufacturing processes, and establishing clear regulatory guidelines. These developments promise to accelerate the clinical translation of nanodiagnostics, ultimately making them more accessible, reliable, and essential for the early detection of cancer, infections, and genetic disorders in both high- and low-resource settings.

6. Smart and Responsive Nanoplatforms:

6.1. Stimuli-Responsive Nanoparticles (pH, Heat, Enzymes)

Smart drug delivery systems have introduced a revolutionary chapter in nanomedicine, and among them, stimuli-responsive nanoparticles (SRNPs) are particularly noteworthy for their ability to selectively release therapeutic agents in response to specific internal or external cues. These include pH changes, temperature fluctuations, redox states, and enzymatic activity. Such systems enhance treatment efficacy by improving targeting and minimizing systemic toxicity, especially in diseases like cancer and inflammation, where the microenvironment deviates significantly from that of healthy tissues.

Stimuli-responsive nanoparticles are designed to remain inert under normal physiological conditions but undergo structural transformations or degradation upon encountering targeted environmental triggers. These triggers fall into two main categories: internal (or endogenous), such as pH changes, enzyme activity, and redox gradients, and external (or exogenous), including temperature, light, ultrasound, and magnetic fields. This responsive design enables site-specific drug delivery while reducing off-target effects and premature drug leakage.

One of the most explored stimuli is pH. pH-responsive nanoparticles exploit the acidic environments found in tumors (pH ~6.5–6.8), endosomes (pH ~5.5–6), and lysosomes (pH ~4.5–5.5), as compared to normal tissue (pH ~7.4). Several design strategies are employed to achieve pH sensitivity, such as incorporating acid-labile linkers like hydrazone or imine, using charge-conversion polymers that switch from hydrophobic to hydrophilic in acidic conditions, and employing polyelectrolyte multilayers that respond to pH shifts by swelling or collapsing. Biodegradable polymeric systems like poly(lactic-co-glycolic acid), poly(γ-glutamic acid), and polyacrylic acid have shown promise in achieving controlled, tumor-specific drug release (Bhattacharya *et al.,* 2023; Sethuraman *et al.,* 2021).

Thermoresponsive, or heat-sensitive, nanoparticles are another important class. These are typically activated under hyperthermic conditions (40–45°C), which can occur naturally in inflamed tissues or be induced through methods like photothermal therapy or focused ultrasound. Commonly used materials include polymers such as poly(N-isopropylacrylamide) (PNIPAM), which undergo a phase change above their lower critical solution temperature (LCST), liposomes that become permeable at elevated temperatures, and gold nanoshells or nanorods that generate localized heat upon exposure to near-infrared (NIR) light. Dual-responsive systems combining both pH and temperature sensitivity have also been developed using diblock copolymers, which remain stable at physiological temperature and release their payload under acidic, heated conditions (Pytlíková *et al.,* 2024).

Enzyme-responsive nanoparticles leverage the overexpression of specific enzymes in pathological sites. These include matrix metalloproteinases (MMPs) in tumors, proteases in bacterial infections and inflammation, and hyaluronidase in metastatic cancers. Nanoparticles incorporating enzyme-sensitive linkers or polymers can release drugs selectively in environments where these enzymes are abundant. Wu et al. (2020) described nanoparticles responsive to both pH and enzymatic cleavage for synergistic chemotherapy and imaging, while Hughes et al. (2023) reviewed soft nanoparticles with cleavable motifs tailored for intracellular targeting in inflammatory conditions.

To further refine specificity and control, researchers have developed dual- and multi-stimuli responsive systems that react to combinations such as pH and redox, pH and enzyme, or pH and heat, as well as external triggers like light and magnetic fields. These

designs provide on-demand control of drug release, especially in cancer, where multiple abnormalities coexist. For example, Kim et al. (2023) developed silica nanoparticles that are both pH- and temperature-sensitive, showing enhanced doxorubicin release in acidic and hyperthermic tumor environments. Similarly, Dongxue *et al.,* (2019) reported on poly(γ-glutamic acid)-cysteine-chitosan nanoparticles with pH/redox dual responsiveness that demonstrated improved uptake and cytotoxicity in cancer cell lines.

Although oncology remains the primary focus for SRNPs, these systems are also showing promise in other fields. In diabetes, glucose-oxidase-triggered insulin release has been achieved; in autoimmune diseases, redox-responsive nanocarriers exploit oxidative tissue environments for localized drug release; and in infectious diseases, enzyme-activated nanoparticles deliver antimicrobial peptides where bacterial enzymes are present. Zhou *et al.,* (2021) discussed metal-organic frameworks (MOFs) engineered to respond to multiple stimuli, including pH, ATP, and microRNA, offering intelligent delivery strategies for infections and thrombosis.

The advantages of SRNPs are numerous. They enable controlled and localized drug release, improve drug stability and circulation half-life, minimize systemic toxicity, and can even be combined with imaging functions in theranostic applications. However, several limitations must be addressed. These include the complexity and cost of synthesis, scalability for commercial production, variability in patient-specific stimuli that may affect performance, and regulatory challenges associated with approving multi-component systems.

Future development of SRNPs is likely to focus on creating biodegradable and biosafe materials suitable for clinical use, precision-engineered polymers capable of programmable drug release, and integration with biosensors and artificial intelligence to support real-time, closed-loop delivery systems. Clinical trials will be essential to validate their efficacy and safety in human populations. The continued advancement of dual- and multi-responsive platforms holds enormous potential to realize the vision of personalized, precision nanomedicine.

6.2. Theranostic Systems for Real-Time Monitoring and Feedback

In recent years, the integration of diagnostic and therapeutic capabilities within a single nanoplatform—termed theranostics—has emerged as a transformative approach in personalized medicine. These multifunctional nanoplatforms enable simultaneous disease detection, targeted treatment, and real-time monitoring of therapeutic responses, dramatically enhancing treatment precision, reducing systemic toxicity, and improving patient outcomes. The core idea of theranostics is to combine "therapy" and "diagnostics" into one system, allowing nanoparticles to deliver therapeutic agents such as drugs, genes, or proteins while also carrying imaging components that facilitate non-invasive visualization of their behavior and therapeutic impact within the body. This dual-functionality ensures early diagnosis, continuous monitoring, improved targeting accuracy, and real-time decision-making that tailors treatment to each patient's unique condition (Raheem *et al.,* 2023; Carrese *et al.,* 2022).

A typical theranostic nanoparticle includes a therapeutic payload—such as chemotherapeutic drugs, nucleic acids like siRNA or mRNA, or photothermal agents—paired with a diagnostic component like fluorescent dyes, MRI contrast agents, or PET tracers. Targeting ligands, such as antibodies or peptides, are incorporated to ensure specific binding to disease biomarkers, while the entire complex is housed within a biocompatible matrix composed of materials like polymers, lipids, gold, silica, or magnetic nanoparticles. These systems enable a broad range of imaging techniques—including MRI, CT, PET, photoacoustic, fluorescence, and thermal imaging—to track biodistribution and evaluate therapeutic efficacy in real time (Raka *et al.,* 2024; Ikbal *et al.,* 2024).

Cancer has been the most studied application area for theranostic nanoparticles due to its complexity and urgent need for precision medicine. Real-time imaging enables visualization of nanoparticle accumulation in tumors, continuous evaluation of treatment responses, and dynamic adjustments to therapy regimens. Hybrid nanoparticles (HNPs) that combine gold and polymeric matrices have been developed to co-deliver chemotherapeutics and imaging agents, utilizing the enhanced permeability and retention (EPR) effect to localize selectively within tumor tissues (Raka *et al.,* 2024). A particularly notable design featured a temperature-sensitive lipid-based nanoplatform incorporating infrared dyes and upconversion nanoparticles, which supported five imaging modalities—MRI, CT, upconversion luminescence (UCL), photoacoustic, and thermal imaging—thereby enabling comprehensive monitoring alongside targeted photothermal therapy (Xu *et al.,* 2021).

The integration of therapeutic and diagnostic feedback in these platforms allows for intelligent treatment modulation. For example, drug dosages can be recalibrated based on measured nanoparticle accumulation at the target site, and ineffective therapies can be stopped early to prevent unnecessary side effects. Therapy progress can be tracked non-invasively, reducing the need for repeated biopsies. Some polymer-based theranostic systems even release drugs in response to local tumor conditions such as pH, redox levels, or specific enzymes, while simultaneously reporting the release event through imaging cues (Hosseini *et al.,* 2023).

Multimodal imaging is a major feature of advanced theranostic systems. By combining complementary imaging techniques—such as MRI-PET for anatomical and molecular data, photoacoustic-fluorescence for high-resolution and deep-tissue visualization, or CT-UCL for metabolic and structural insights—researchers have enhanced the spatial and temporal accuracy of disease tracking and therapeutic assessment (Sharma *et al.,* 2021; Fernandes, 2023). These capabilities are essential in applications like photothermal therapy, where gold nanoshells absorb near-infrared light and convert it into heat to selectively destroy tumor cells, with real-time thermal feedback ensuring precise control. Similarly, photoacoustic imaging of light-activated drug-loaded nanoparticles enables visual confirmation of drug release and spatially resolved therapeutic action. In immunotherapy, theranostic imaging is increasingly used to track the behavior of therapies like CAR-NK cells, ensuring proper targeting while minimizing off-target toxicity (Xu *et al.,* 2021).

Theranostics is not confined to oncology. In cardiovascular medicine, they are being used for plaque imaging and thrombolytic drug delivery. In neurology, blood-brain barrier-penetrating nanoparticles show promise for diagnosing and treating conditions like Alzheimer's disease. Infectious diseases also benefit from this technology, with nanoparticles enabling localized antibiotic delivery alongside real-time imaging of infection sites.

Despite their immense potential, theranostic systems face several challenges. The complexity of synthesizing multifunctional nanoparticles, the long-term toxicity and biocompatibility of nanomaterials, and the difficulty of scaling production for clinical use all pose significant hurdles. Moreover, many of these platforms remain in preclinical stages due to regulatory and safety testing barriers. Rigorous clinical validation, reproducibility, and cost-effectiveness studies are necessary before these systems can achieve mainstream adoption (Shetty & Chandra, 2020).

Looking to the future, the field is advancing toward the development of single-component theranostic agents that combine all functions in a simplified structure with fewer safety risks (Cai *et al.,* 2021). Artificial intelligence is also being integrated into theranostic platforms to enable real-time analysis of imaging data, guiding adaptive drug delivery with high precision.Additionally, miniaturized theranostic devices—including wearable or implantable microdevices—are being explored for continuous drug administration and biomarker tracking in chronic disease management.In conclusion, theranostic systems offer a groundbreaking advancement in nanomedicine by providing real-time feedback, precise targeting, and truly personalized treatment strategies. While several barriers to clinical application remain, the rapid evolution of these integrated nanoplatforms signals a promising future in the management of complex diseases such as cancer and beyond.

6.3. AI-Integrated Nanodevices for Adaptive Therapeutics

The convergence of artificial intelligence (AI) and nanotechnology is ushering in a new era of medicine, particularly in the domain of adaptive therapeutics. AI-integrated nanodevices are engineered to sense, analyze, and respond to physiological signals, enabling personalized drug delivery, real-time feedback, and finely controlled therapeutic interventions. These advanced systems are redefining drug formulation and delivery by offering dynamic adaptability, leading the way toward autonomous medical systems that can self-adjust to a patient's ever-changing biological landscape.

These nanodevices merge the precision of nanotechnology with the decision-making capacity of AI. On the nanoscale, they can deliver drugs, monitor biomolecular activity, or stimulate tissues, while AI components process real-time data to support decision-making, pattern recognition, and adaptive control. Together, they form closed-loop therapeutic systems that evolve alongside the patient's response to treatment (Heydari *et al.,* 2024; Kapoor *et al.,* 2024). AI algorithms such as machine learning (ML) and deep learning (DL) are used to model and predict drug release kinetics, nanoparticle behavior in vivo, and optimal dosing regimens. These models are trained on vast datasets—including patient histories, molecular profiles, and pharmacological properties—to forecast nanoparticle biodistribution, automate nanocarrier design, and reduce variability in formulation processes. For instance, AI-powered platforms can anticipate how nanoparticles will interact with immune cells or predict their clearance rates based on surface chemistry and other modifications (Edriss *et al.,* 2025; Colombo, 2020).

One of the key innovations of AI-integrated nanodevices is their capacity for adaptive feedback and decision-making. These systems monitor local drug concentrations or biomarkers, evaluate the effectiveness of the ongoing treatment, and either continue, modify, or suspend further drug release accordingly. This feedback mechanism is akin to how insulin pumps adjust dosing in real time based on glucose levels. In oncology, AI-enabled nanosystems are already being developed to detect early tumor responses and modify treatment strategies accordingly (Heydari *et al.,* 2024). Advanced AI models like adaptive neuro-fuzzy inference systems (ANFIS), multilayer perceptrons (MLP), and genetic algorithms (GA) have been applied to optimize nanoparticle characteristics including particle size, surface charge, drug loading efficiency, and controlled release rates. Cuckoo search algorithms and ANFIS, in particular, have demonstrated robust performance in fine-tuning nanoparticle properties for enhanced

targeting and reduced side effects (Villaseñor-Cavazos *et al.,* 2022).

The clinical potential of AI-guided nanodevices spans a range of diseases. In cancer therapy, they are used to identify tumor markers, deliver chemotherapy agents, and monitor treatment progress, adjusting drug doses based on tumor shrinkage or immune responses. In cardiovascular diseases, AI-enabled nanoparticles detect unstable plaques and deliver clot-dissolving agents in real time (Vélez-Reséndiz & Vélez-Arvízu, 2019). For neurological disorders, these smart particles can cross the blood-brain barrier and target inflamed neurons, releasing neuroprotective compounds in response to specific inflammatory or electrical cues. Respiratory therapy has also benefited, as exemplified by LungVis 1.0—an AI-powered system that integrates 3D imaging and nanoparticle delivery. It uses fluorescence microscopy and deep learning to map drug distribution in lung tissue, optimize dose placement, and monitor immune cell interactions, with AI automating data interpretation and treatment adjustments (Yang *et al.,* 2024).

DNA nanotechnology is also being enhanced by AI. Programmable nanodevices constructed from DNA can respond to multiple physiological cues such as pH and ATP levels. The "dual-key-and-lock" DNA nanodevice, for example, releases therapeutic agents only in the presence of both stimuli, ensuring precision. When AI is incorporated, such systems become even more powerful, capable of self-regulation in complex, dynamic disease environments (Yue *et al.,* 2024). Despite these advancements, ethical and regulatory challenges persist. AI systems rely heavily on sensitive patient data, raising privacy concerns. There is also the issue of algorithmic transparency—clinicians must be able to understand and trust the AI's decisions. Regulatory frameworks are not yet fully equipped to evaluate adaptive and autonomous systems, making clinical approval a slow process (Aundhia *et al.,* 2024).

Looking ahead, the integration of AI and nanodevices promises to advance personalized medicine in unprecedented ways. Future systems will offer fully customized nanoparticle designs for individual patients, autonomous feedback loops where diagnostics and therapeutics co-exist, and remote patient monitoring using wearable nanosensors. Emerging technologies such as the Internet of Bio-NanoThings (IoBNT) envision networks of nanodevices communicating within the body to coordinate responses to complex diseases (El-Fatyany *et al.,* 2020). The fusion of AI with edge computing, quantum algorithms, and biomimetic materials is expected to enhance the intelligence, sensitivity, and adaptability of these platforms even further.

In conclusion, AI-integrated nanodevices represent a paradigm shift in therapeutic delivery, enabling real-time, intelligent interventions that can adapt on the fly. These systems hold extraordinary potential to make treatment more precise, personalized, and efficient. Although challenges remain in terms of ethics, data governance, and regulatory approval, the accelerating pace of innovation makes it clear that AI-guided nanomedicine is rapidly moving from concept to clinical reality.

7. Clinical Translation and Regulatory Perspectives

7.1. FDA-Approved Nanodrugs and Vaccines: Case Studies

The translation of nanomedicines from laboratory research to clinical application has accelerated remarkably in recent years, particularly following the global success of lipid nanoparticle (LNP)-based mRNA vaccines during the COVID-19 pandemic. The U.S. Food and Drug Administration (FDA) has approved a diverse portfolio of nanodrugs and nanovaccines that offer substantial improvements in pharmacokinetics, targeted drug delivery, and therapeutic efficacy compared to traditional pharmaceutical formulations. These case studies highlight the most impactful FDA-approved nanomedicine products and their clinical relevance.

Among the most prominent nanomedicine milestones are the Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1273) COVID-19 vaccines. These mRNA-based vaccines utilize lipid nanoparticles to encapsulate and protect mRNA encoding the SARS-CoV-2 spike protein. The LNPs shield the fragile genetic material from enzymatic degradation and promote its efficient cellular uptake, triggering strong and durable immune responses with minimal adverse effects. The global deployment and efficacy of these vaccines have not only demonstrated the power of nanotechnology in public health crises but also expanded the horizon for RNA-based therapies in areas such as oncology and rare genetic disorders (Souto *et al.,* 2024).

A landmark in cancer nanotherapy, Doxil® (approved in 1995) was the first FDA-approved nanodrug and remains a foundational example of liposomal drug delivery. It encapsulates the chemotherapeutic agent doxorubicin in PEGylated liposomes, significantly improving the drug's bioavailability and reducing its notorious cardiotoxicity. Used to treat ovarian cancer, multiple myeloma, and AIDS-related Kaposi's sarcoma, Doxil® benefits from an extended circulation half-life and targeted tumor accumulation. Long-term clinical data have shown a consistent reduction in adverse effects, reinforcing the utility of nanocarriers in improving the therapeutic index of cytotoxic agents (Ahamad *et al.,* 2020).

Another innovative nanodrug, Abraxane® (approved in 2005), is a nanoparticle albumin-bound formulation of paclitaxel. It was developed to address the limitations of conventional paclitaxel, which requires

toxic solvents such as Cremophor EL for solubilization. Abraxane® eliminates the need for such solvents, reducing hypersensitivity reactions while enhancing tumor penetration and drug bioavailability. The albumin-bound system exploits natural transport mechanisms like gp60 receptor-mediated transcytosis and has become a benchmark in biomimetic nanotechnology for the treatment of breast, lung, and pancreatic cancers (Mahaling *et al.,* 2024).

Vyxeos® offers a paradigm shift in combination chemotherapy. It is a dual-drug liposomal formulation combining daunorubicin and cytarabine in a fixed molar ratio (5:1), tailored for treating high-risk acute myeloid leukemia (AML). This synchronized delivery via a liposomal platform enhances drug synergy and pharmacodynamics. Clinical studies have demonstrated that Vyxeos® provides superior overall survival compared to traditional chemotherapy regimens, setting a new standard for rationally designed combination nanotherapies in hematologic malignancies (Straehla, 2024).

Onpattro® (patisiran), approved in 2018, further illustrates the clinical maturation of RNA-based nanotherapies. It is the first siRNA drug delivered using lipid nanoparticles to silence the transthyretin (TTR) gene in patients with hereditary transthyretin-mediated amyloidosis. The formulation features DLin-MC3-DMA, an ionizable lipid essential for efficient endosomal escape and hepatic targeting. Onpattro®'s success has laid the foundation for the expansion of LNP-based therapies into other genetic and metabolic disorders, validating this delivery strategy beyond the realm of vaccines (Souto *et al.,* 2024).

Nanovaccines based on polyanhydride nanoparticles are also gaining momentum, especially in veterinary applications and biodefense. These particles serve dual functions as antigen carriers and immune adjuvants. For instance, polyanhydride-based nanovaccine platforms delivering the F1-V antigen have shown rapid and durable protection against pneumonic plague in preclinical models. Their intrinsic adjuvanticity and antigen stability reduce the need for booster doses and cold-chain logistics (Wagner *et al.,* 2019). In veterinary medicine, a bovine respiratory syncytial virus (BRSV) nanovaccine tested in calves achieved robust mucosal and systemic immunity, suggesting translatable potential for human respiratory vaccines as well (Maina *et al.,* 2023).

A novel strategy to address antidrug antibody (ADA) resistance involves lipid-based rapamycin nanovaccines. These formulations are designed to modulate antigen-presenting cells and restore immune tolerance to biologics such as pegylated uricase and AAV vectors. By selectively reprogramming immune responses without compromising host defense, lipid-rapamycin nanovaccines illustrate the precision of nanotechnology in immune regulation and offer promising solutions for maintaining the efficacy of biologic therapies (Li *et al.,* 2025). Collectively, these FDA-approved nanomedicine products underscore the clinical viability of nanotechnology in addressing unmet medical needs. They exemplify how nanocarriers can revolutionize drug solubility, targeting, bioavailability, and safety, while opening doors to personalized and precision medicine across multiple therapeutic domains.

7.2. Regulatory Challenges in Safety, Efficacy, and Manufacturing

Despite the immense potential of nanomedicine to revolutionize diagnostics and therapeutics, its clinical translation faces formidable regulatory challenges. The inherent complexity of nanoscale materials—ranging from their dynamic physicochemical properties to multifunctional mechanisms of action—creates difficulties in establishing standardized safety, efficacy, and manufacturing protocols. These issues are compounded by limited historical data, evolving scientific understanding, and inadequate harmonization across international regulatory bodies.

One of the most pressing obstacles is the complexity involved in characterizing nanomedicine products. Unlike traditional small-molecule drugs, nanomedicines often consist of structurally diverse, multi-component systems such as liposomes, polymeric nanoparticles, and dendrimers. Characterizing essential parameters such as particle size, surface charge, shape, and stability is technically challenging and often lacks standardization. Moreover, minor variations in the manufacturing process can lead to significant changes in pharmacokinetics and biodistribution. Regulatory definitions themselves are inconsistent—while both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) adopt size-based definitions (approximately 1–100 nm), this criterion alone fails to fully capture the functional and structural complexities of nanomedicines. Thus, advanced tools such as dynamic light scattering, zeta potential analysis, and high-resolution microscopy must be integrated into regulatory workflows to ensure comprehensive characterization (Csóka *et al.,* 2021; Ali *et al.,* 2022).

Another significant challenge lies in safety assessment. Nanotoxicology must address both the active pharmaceutical ingredient and the nanocarrier, especially given the propensity of nanoparticles to accumulate in off-target tissues like the liver and spleen, potentially triggering immune responses or oxidative stress. The unique ability of nanoparticles to cross biological barriers and enter cells via endocytosis necessitates new toxicokinetic models. Long-term safety data remain limited, particularly for chronic use. Metallic nanoparticles such as silver and gold raise additional concerns due to their potential to persist in biological systems and cause biocompatibility issues (Chaudhari & Panchave, 2022; De Jong *et al.,* 2022). To address these

risks, regulators now recommend a tiered, risk-based approach that evaluates nanomedicine safety based on composition, degradation kinetics, and cellular interactions.

Demonstrating efficacy is another regulatory bottleneck, particularly for multifunctional or combination nanotherapies such as theranostics. These therapies often depend on complex integrated mechanisms—such as ligand targeting, stimuli-responsive drug release, or dual-drug delivery—which complicates trial design and outcome measurement. Furthermore, the absence of a standardized framework for bioequivalence makes it difficult to evaluate follow-on products, known as "nanosimilars," which cannot be assessed through conventional pharmacokinetic metrics alone (Hertig *et al.,* 2021; Salvi *et al.,* 2024). New regulatory strategies must accommodate surrogate endpoints and adaptive trial designs that reflect the unique behaviors of nanomedicines in vivo.

On the manufacturing front, achieving reproducibility and scalability is a critical concern. Nanomedicine manufacturing is sensitive to multiple variables—mixing speeds, solvent evaporation, temperature, and equipment configuration—all of which influence nanoparticle quality. Regulatory agencies emphasize the use of Quality by Design (QbD) frameworks to identify critical process parameters (CPPs) and critical quality attributes (CQAs) during development. However, challenges remain in real-time release testing and process control due to a lack of predictive models and standardized in-process assays (Ramos *et al.,* 2022; Singh *et al.,* 2024). Additionally, sterilization and storage conditions can affect nanoparticle morphology, aggregation, and bioactivity, adding another layer of complexity to the regulatory pathway.

Global harmonization remains inadequate. While the FDA, EMA, and Japan's Pharmaceuticals and Medical Devices Agency (PMDA) have established frameworks for nanotechnology regulation, many countries—particularly in the developing world—lack the institutional infrastructure to evaluate nanomedicine products. Discrepancies in documentation, classification systems, and evaluation methodologies hinder cross-border clinical trials and delay international approvals. Initiatives like the International Pharmaceutical Regulators Programme (IPRP) and the World Health Organization's nanotechnology roadmap are vital in aligning global standards and facilitating access to nano-enabled therapies (Nyazema *et al.,* 2023; Damjanovska *et al.,* 2023).

Beyond technical hurdles, emerging ethical, legal, and social implications (ELSI) must also be addressed. The use of AI-guided and personalized nanomedicine systems raises concerns about data privacy, consent, and algorithmic transparency. Moreover, intellectual property frameworks must be adapted to handle the patenting of complex, multifunctional nanomedicine systems. Issues of access and equity are also pressing; there is a risk that advanced nanotherapies may become confined to wealthier healthcare systems, further widening global health disparities (Souto *et al.,* 2024). International bioethical guidelines and patent harmonization will be essential to support equitable and responsible innovation.

Encouragingly, regulatory science is beginning to evolve to meet these challenges. Initiatives like REFINE and NANoREG have established advanced modeling and risk assessment templates tailored for nanomedicine evaluation. Programs such as the FDA's Breakthrough Therapy Designation and the EMA's PRIME scheme provide adaptive pathways to accelerate the approval of high-need nanotherapies. Digital tools and AI are also being incorporated to support predictive modeling of nanoparticle behavior and safety profiles, potentially streamlining regulatory submissions (Musazzi *et al.,* 2023). However, these innovations will only succeed if accompanied by robust data standardization, reproducibility, and interdisciplinary collaboration between scientists, regulators, and clinicians.

In summary, while nanomedicine offers revolutionary potential, its regulatory journey is fraught with complexity. Addressing challenges in characterization, safety, efficacy, and global harmonization requires coordinated efforts, innovative tools, and updated policy frameworks that can keep pace with scientific advances. Only through such comprehensive strategies can the promise of nanotechnology be fully realized in safe, effective, and accessible healthcare solutions.

7.3. **Scaling Nanomedicine from Bench to Bedside**

The successful clinical translation of nanomedicine hinges not only on demonstrating preclinical efficacy but also on overcoming significant challenges in scalability, reproducibility, and compliance with regulatory manufacturing standards. As promising nanoparticle-based therapies transition from academic laboratories into pharmaceutical pipelines, maintaining consistent nanoparticle characteristics, ensuring batch-to-batch reproducibility, and aligning production with good manufacturing practices (GMP) become critical. Unlike traditional small-molecule drugs, nanomedicines involve multi-component systems that are highly sensitive to variations in particle size, surface charge, shape, and composition—factors influenced by even minor changes in processing parameters such as mixing speed, solvent ratio, temperature, and drying techniques. Laboratory methods such as solvent evaporation, emulsification, or nanoprecipitation offer precision at small scales but often yield different results when applied to industrial volumes. For instance, scale-up studies with squalene-adenosine nanoparticles reported alterations in

size and surface properties despite following the same protocols, highlighting the unpredictable behavior of nanoparticle systems during expansion (Dormont *et al.,* 2019). Furthermore, batch-to-batch variability in polymer synthesis and nanoparticle assembly poses major reproducibility issues, often necessitating complete re-optimization of formulation parameters (Patel *et al.,* 2021).

Despite these difficulties, several case studies offer valuable insight into effective scale-up strategies. The use of Flash NanoPrecipitation (FNP) for lumefantrine-loaded nanoparticles successfully maintained consistent particle size (~200 nm) across multiple mixer sizes and production scales, leveraging identical Reynolds numbers to preserve dynamic similarity (Feng *et al.,* 2019). Likewise, chitosan-based polymeric micelles retained critical physicochemical properties after scale-up using cross-flow filtration and demonstrated extended storage stability at sub-zero temperatures (Almeida *et al.,* 2021). These examples illustrate how scale-invariant techniques—such as microfluidics, high-pressure homogenization, and spray drying—can facilitate reliable manufacturing for clinical and commercial application.

To mitigate risks associated with scale-up, the pharmaceutical industry has increasingly adopted Quality by Design (QbD) frameworks. These involve identifying critical quality attributes (CQAs) and critical process parameters (CPPs) early in development and engineering processes that consistently meet predefined product specifications. In the context of nanomedicine, QbD relies on real-time analytical controls including nanoparticle tracking analysis (NTA), dynamic light scattering (DLS), zeta potential measurement, and encapsulation efficiency assessments, all of which are vital for maintaining nanoparticle uniformity, stability, and functionality (Csóka *et al.,* 2021). QbD not only enhances production consistency but also streamlines regulatory submissions by producing comprehensive datasets to support investigational new drug (IND) applications and clinical trial progression.

Nevertheless, economic and regulatory barriers remain substantial. The lack of harmonized global standards for nanomedicine production creates inconsistencies across manufacturing protocols and regulatory expectations. Despite guidance from the FDA and EMA, no universal thresholds exist for critical nanoparticle parameters such as drug release kinetics or size distribution. The specialized equipment, sterile environments, and advanced analytics required to produce nanomedicines also elevate production costs, potentially limiting accessibility in low-resource regions (Djordjevic *et al.,* 2021). Compounding the issue, academic formulations are often developed with custom lab equipment not compatible with industrial workflows, making technology transfer between research institutions and manufacturing firms inefficient.

To address these challenges, continuous-flow chemistry and automated microfluidic systems are gaining momentum. These platforms offer precise control over reagent flow, mixing dynamics, and reaction kinetics, reducing variability while increasing throughput. For instance, high-shear mixing and membrane extrusion have been used to scale up PLGA nanoparticle production with excellent reproducibility and monodispersity (Operti *et al.,* 2021). Flash NanoPrecipitation systems also enable downstream spray drying to generate solid-state nanomedicines suitable for oral or pulmonary delivery. Real-time analytics—such as UV-Vis spectroscopy and multi-angle light scattering—are integrated directly into manufacturing lines to provide quality assurance without interrupting production (Tang *et al.,* 2024).

Bridging the gap between preclinical success and clinical readiness also requires innovative translational tools. Traditional animal models often fail to accurately predict human responses to nanoparticle formulations due to species-specific differences in immune responses and biodistribution. To overcome this, translational imaging and pharmacodynamic modeling are being used to simulate clinical outcomes. One example involves scaling a simvastatin-loaded HDL nanoparticle system from rodents to larger animals using PET/MRI imaging to monitor biodistribution and optimize dosing regimens before initiating clinical trials (Binderup *et al.,* 2019). This multidisciplinary approach—combining pharmacology, imaging, bioengineering, and regulatory science—is key to preparing nanomedicine candidates for human application.

Collaborative models are also emerging to support commercial translation. Public-private partnerships, such as the EU's REFINE initiative and the U.S. National Cancer Institute's Nanotechnology Characterization Lab (NCL), provide infrastructure and expertise for nanomedicine validation, safety testing, and regulatory alignment. Contract manufacturing organizations (CMOs) specializing in sterile nanoformulation have also become indispensable partners for startups lacking in-house GMP capabilities. Furthermore, evolving intellectual property strategies are necessary to protect complex, multi-component nanotherapeutics, which may require layered patents on formulation technologies, delivery methods, and therapeutic mechanisms (Zhang & Liang, 2021).

Looking ahead, the future of nanomedicine scale-up is moving toward modular, personalized platforms. Innovations such as AI-assisted nanoparticle design, 3D-printed nano-drug carriers, and digital twins for formulation modeling are being explored to accelerate development and tailor treatment to individual patients. The success of these strategies depends on standardized protocols and regulatory convergence,

especially across international markets. Additionally, cost-reduction approaches—including biodegradable carrier materials and reusable microfluidic systems—may help extend the reach of nanomedicine to underserved populations and global health applications.

8. Ethical, Societal, and Economic Implications

8.1. Ethical Issues in Human Enhancement and Surveillance

Human enhancement technologies (HETs) introduce significant ethical challenges, particularly around bodily autonomy, fairness, and societal pressure to enhance. Researchers have raised concerns about the lack of oversight and guidance, leading to calls for structured ethical frameworks to manage risks in development and application (Erden & Brey, 2021). Efforts to regulate these technologies have led to proposed guidelines such as those adopted by the European Commission for Horizon Europe, setting an international precedent for ethical governance (Erden & Brey, 2022). A meta-ethical analysis also emphasizes the importance of justifying the very act of ethical inquiry in futuristic technologies (Rueda, 2023).

In the surveillance domain, ethical challenges center on balancing security needs with individual rights. Scholars argue that although surveillance can serve public safety, it often lacks sufficient ethical constraints, potentially undermining privacy and autonomy (Macnish, 2021). This is especially pressing in contexts involving digital data collection, where users may not be fully informed or consent is ambiguous (Fernholz *et al.,* 2025).

8.2. Public Perception and Risk Communication

The societal perception of human enhancement varies significantly, driven by cultural, ethical, and psychological factors. A recent cross-country Q-study identified four distinct attitudes toward insideable enhancement technologies: outright acceptance, conditional support, ambivalence, and rejection—each grounded in unique ethical trade-offs and risk assessments (Gauttier *et al.,* 2024). Furthermore, public understanding of surveillance ethics is shaped by growing awareness of data privacy concerns, especially as environmental and digital traces become more easily collectible. Experts highlight the urgent need for better public communication strategies that address both group and predictive privacy concerns (de Groot, 2023).

8.3. **Cost, Access, and Global Health Equity:**

Access to enhancement technologies and surveillance tools raises pressing equity concerns. While such technologies may promise individual or societal benefit, their costs often limit accessibility to wealthy populations, exacerbating existing health disparities. Scholars argue that equitable access must be embedded into regulatory and research agendas from the outset (Ghafur *et al.,* 2020). Similarly, if not carefully managed, HETs may reinforce global inequities in health outcomes, as the benefits of such technologies disproportionately accrue to the Global North. This underscores the importance of establishing global ethical standards and cost-sharing mechanisms to ensure broader access (Ellison, 2024).

9. Future Directions and Grand Challenges

9.1. **Emerging Technologies: DNA Origami, Nanobots, and Biohybrids**

Emerging nanotechnologies like DNA origami, nanobots, and biohybrids represent a new frontier in precision medicine and biotechnology. DNA origami enables the creation of nanoscale structures with high precision, capable of targeted drug delivery, biosensing, and vaccine development (Li *et al.,* 2024; Wang *et al.,* 2021). Its programmable nature allows for precise control over molecule arrangement, orientation, and functionality (Zhao *et al.,* 2024).

Nanobots, especially those based on DNA, have shown great promise in cancer therapy. These self-assembled constructs can deliver payloads such as thrombin or doxorubicin directly to tumor sites, reducing side effects and improving efficacy (Singh & Deshmukh, 2022). Similarly, biohybrid systems that integrate biological and synthetic components are advancing toward real-time therapeutic and diagnostic functions.

Despite their potential, challenges such as biostability, immune compatibility, and manufacturing scalability remain active research areas (Aye & Sato, 2022).

9.2. **Integrating Nanotechnology with Genomics and Systems Biology**

A promising avenue lies in integrating DNA nanotechnology with genomics and systems biology. Programmable DNA nanostructures can interact with genetic materials to modulate gene expression, serve as scaffolds for CRISPR delivery, or enable spatial genome editing (Ghosal *et al.,* 2023). This convergence is also aiding in single-cell analysis and personalized medicine, offering nanoscale tools to analyze, edit, and reprogram cellular pathways.

Efforts in this direction aim to create closed-loop systems where nanoscale devices sense molecular conditions and respond dynamically. Such integration holds promise for next-generation synthetic biology platforms and intelligent therapeutic systems (Gangrade *et al.,* 2021).

9.3. **Open Questions and Vision for the Next Decade**

Key open questions include:

- How can we enhance the long-term biocompatibility and stability of nanostructures in vivo?
- What ethical frameworks are necessary for regulating autonomous biohybrid systems?

- Can large-scale, cost-effective manufacturing be achieved without compromising function or precision?

The vision for the next decade includes a shift toward autonomous, programmable, and adaptive nanodevices capable of functioning within complex biological systems. Researchers foresee a future where these systems not only treat but also monitor and adapt to disease progression in real time (Loretan *et al.,* 2020; Ameixa *et al.,* 2024).

REFERENCES

- Damjanovska, G., Karanakov, L., & Georgievska, K. Z. (2023). Nanomedicines and off patent follow-on medicines (nanosimilars): EMA regulatory procedures overview. *Macedonian Pharmaceutical Bulletin*.
- Ding, T., Yang, J., Pan, V., Zhao, N., Lu, Z., Ke, Y., & Zhang, C. (2020). DNA nanotechnology assisted nanopore-based analysis. *Nucleic Acids Research*.
- Joseph, J., & Augustine, R. (2021). Nanomaterials as multifaceted structural and functional materials. *Applied Innovations in Chemistry and Materials*, 1(1), 2–2.
- Kalangi, S. K., & Bhosale, R. (2022). Editorial: New approaches in toxicity testing of nanotherapeutics. *Frontiers in Pharmacology, 13*.
- Lam, F. C. (2022). Editorial: Nano-imaging in translational cancer medicine. *Frontiers in Bioengineering and Biotechnology, 10*.
- Patel, J., Patel, A. P., & Bhatia, D. (2021). Introduction to nanomaterials and nanotechnology. In *Emerging Technologies for Nanoparticle Manufacturing*.
- Sivakami, A., Sarankumar, R., & Vinodha, S. (2021). Introduction to nanobiotechnology: Novel and smart applications. In *Bio-manufactured Nanomaterials.*
- Yanar, F., Carugo, D., & Zhang, X. (2023). Hybrid nanoplatforms comprising organic nanocompartments encapsulating inorganic nanoparticles for enhanced drug delivery and bioimaging applications. *Molecules, 28*(15), 5694.
- Yang, C., Lin, Z., Chen, J.-A., Xu, Z., Gu, J., Law, W., Yang, J., & Chen, C.-K. (2021). Organic/inorganic self-assembled hybrid nano-architectures for cancer therapy applications. *Macromolecular Bioscience, 21*(11), e2100349.
- Park, W., Shin, H., Choi, B., Rhim, W., Na, K., & Han, D. K. (2020). Advanced hybrid nanomaterials for biomedical applications. *Progress in Materials Science, 114*, 100686.
- Mehta, S., Suresh, A., Nayak, Y., Narayan, R., & Nayak, U. (2022). Hybrid nanostructures: Versatile systems for biomedical applications. *Coordination Chemistry Reviews, 462*, 214482.
- Beltrán-Gracia, E., López-Camacho, A., Higuera-Ciapara, I., Velázquez-Fernández, J. B., & Vallejo-Cardona, A. A. (2019). Nanomedicine review: Clinical developments in liposomal applications. *Cancer Nanotechnology, 10*(1), 11.
- Hussain, Z., Khan, S., Imran, M., Sohail, M., Shah, S. W. A., & de Matas, M. (2019). PEGylation: A promising strategy to overcome challenges to cancer-targeted nanomedicines: A review of challenges to clinical transition and promising resolution. *Drug Delivery and Translational Research, 9*(4), 721–734.
- John, R. (2023). Advances in nanoparticle design for deep tissue penetration and retention. *Journal of Nanobiotechnology, 21*(1), 56–64.
- Moraes, C. M., Barbosa, A. I., Cabral, J. M. S., & Reis, R. L. (2021). Size-dependent interactions of nanoparticles with biological systems. *Journal of Controlled Release, 334*, 211–222.
- Rahman, W. N., Bishara, N., Ackerly, T., He, C. F., Jackson, P., Wong, C., & Davidson, R. (2013). Enhancement of radiation effects by gold nanoparticles for superficial radiation therapy. *Nanomedicine: Nanotechnology, Biology and Medicine, 9*(4), 547–553.
- Singh, N. (2016). Biological interactions of charged nanoparticles: Role of surface charge in protein corona formation and cellular uptake. *International Journal of Nanomedicine, 11*, 69–79.
- Talkar, S., Sahni, J. K., & Ali, J. (2018). Nanocarriers in cancer therapy: An update. *Current Drug Delivery, 15*(2), 191–200.
- Utreja, P., Jain, S., Tiwary, A. K., & Pandit, J. K. (2020). Ligand-anchored liposomes for active targeting of cancer: Current progress and future perspectives. *Critical Reviews in Therapeutic Drug Carrier Systems, 37*(2), 97–126.
- Zolnik, B. S., González-Fernández, Á., Sadrieh, N., & Dobrovolskaia, M. A. (2010). Nanoparticles and the immune system. *Endocrinology, 151*(2), 458–465.
- Gagliardi, A., Irache, J., & Cosco, D. (2023). Editorial: Protein nanoparticles: Characterization and pharmaceutical application. *Frontiers in Pharmacology, 14*.
- Haque, E., & Ward, A. (2018). Zebrafish as a model to evaluate nanoparticle toxicity. *Nanomaterials, 8*(7), 561.
- John, P. (2023). Nanoparticle toxicity may cause testicular dysfunction. *Journal of Environmental Biology, 44*(2).
- Kalangi, S. K., & Bhosale, R. (2022). Editorial: New approaches in toxicity testing of nanotherapeutics. *Frontiers in Pharmacology, 13*.
- Lobaskin, V., Power, D., Lopez, H., & Poggio, S. (2019). Bionano interactions: A key to mechanistic understanding of nanoparticle toxicity. In *Computational Nanotoxicology: Challenges and Perspectives* (pp. 63–86). Jenny Stanford Publishing.

- Rahman, M., Laurent, S., Tawil, N., Yahia, L., & Mahmoudi, M. (2013). Protein-nanoparticle interactions. *Springer Series in Biophysics, 15*, 1–22.
- Yang, C., Yang, J., Lu, A., Gong, J., Yang, Y., Lin, X., Li, M., & Xu, H. H. (2022). Nanoparticles in ocular applications and their potential toxicity. *Frontiers in Molecular Biosciences, 9*.
- Haider, R. (2024). Nanotechnology-Based Targeted Drug Delivery: Current Status and Future Prospects for Drug Development. *Clinical Medical Reviews and Reports*.
- Kumar, V. K., Babu, J. B., Kumar, G. V., Lakshmi, L. L., Aiswarya, M., Deepthi, V. L. S. S. N., & Yaseen, S. K. (2024). Nanocarriers dendrimers. *International Journal of Current Innovations in Advanced Research*.
- Mohapatra, T. K., Behera, P., Patel, P., & Pothal, R. (2024). Nano based drug delivery systems: Emerging trends and future prospects. *International Journal of Pharmaceutical Research and Applications*.
- Shaik, N., & Y, P. (2022). Nanocarriers and their types for targeted drug delivery. *International Journal of Pharmaceutical Sciences Review and Research*.
- Wu, K. Y., Wang, X. C., Anderson, M., & Tran, S. (2024). Advancements in Nanosystems for Ocular Drug Delivery: A Focus on Pediatric Retinoblastoma. *Molecules, 29*.
- Bajaj, G., & Davu, G. (2024). Nanotechnology based drug delivery in cancer treatment: enabling controlled and targeted release of medications. *International Journal of Research in Medical Sciences*.
- Gupta, J., & Sharma, G. (2024). Nanogel: A versatile drug delivery system for the treatment of various diseases and their future perspective. *Drug Delivery and Translational Research*.
- Kumar, A. S., Joshna, N., Saha, G. C., Saha, H., & Billah, M. (2024). A review of recent advancements in nanotechnology for medical drugs delivery. *Research Journal of Pharmacy and Technology*.
- Raheem, A. (2024). Nanotechnology in biomaterials: Revolutionizing drug delivery systems. *Premier Journal of Engineering*.
- Teng, Z., Zhu, X., Zheng, G., Zhang, F., Deng, Y., Xiu, L., Li, W., Yang, Q., & Zhao, D. (2012). Ligand exchange triggered controlled-release targeted drug delivery system based on core–shell superparamagnetic mesoporous microspheres. *Journal of Materials Chemistry, 22*, 17677.
- Zhang, L., Li, Y., & Yu, J. C. (2014). Chemical modification of inorganic nanostructures for targeted and controlled drug delivery in cancer treatment. *Journal of Materials Chemistry B, 2*(5), 452–470.
- Alqudah, A., Aljabali, A. A. A., Gammoh, O., & Tambuwala, M. (2024). Advancements in neurotherapeutics: Nanoparticles overcoming the blood–brain barrier for precise CNS targeting. *Journal of Nanoparticle Research*.
- Bor, G., & Hosta-Rigau, L. (2023). Next generation of brain cancer nanomedicines to overcome the blood–brain barrier (BBB): Insights on transcytosis, perivascular tumor growth, and BBB models. *Advanced Therapeutics, 6*.
- Chaudhuri, T. R., & Straubinger, R. (2019). Nanoparticles for brain tumor delivery. In *Nervous System Drug Delivery*.
- Fu, L., Chung, R., & Shi, B. (2019). Upconversion nanoparticle-based strategy for crossing the blood–brain barrier to treat CNS disease. *Methods in Molecular Biology, 2054*, 263–282.
- Kang, J. H., Cho, J., & Ko, Y. (2018). Effect of nanoparticle size on blood–brain tumor barrier permeability. *Journal of Drug Targeting, 27*, 103–110.
- Kreuter, J. (2021). Application of nanoparticles for drug delivery across the blood–brain barrier. *Advanced Drug Delivery Reviews, 47*, 65–81.
- Lamson, N. G., Pickering, A. J., Wyckoff, J., Ganesh, P., Straehla, J. P., & Hammond, P. (2022). Core material and surface chemistry of LbL nanoparticles direct BBB transport. *bioRxiv*.
- Lim, S. H., Yee, G., & Khang, D. (2024). Nanoparticle-based combinational strategies for overcoming the blood–brain and blood–tumor barriers. *International Journal of Nanomedicine, 19*, 2529–2552.
- Wagner, S., Zensi, A., Wien, S. L., Tschickardt, S., Maier, W., Vogel, T., Worek, F., Pietrzik, C., Kreuter, J., & von Briesen, H. (2012). Uptake mechanism of ApoE-modified nanoparticles on brain capillary endothelial cells. *PLoS ONE, 7*(3).
- Xu, J., Welker, A. M., Miller, B., Calhoun, M., Otero, J., Czeisler, C., Elder, J. B., Beattie, C. E., Gurcan, M. N., Winter, J. O., & Puduvalli, V. K. (2015). Characterization of PolyDots, a novel nanomicelle drug delivery system. *Cancer Research, 75*(15 Suppl), Abstract 3682.
- Cao, Z., Liu, J., & Yang, X. (2024). Deformable nanocarriers for enhanced drug delivery and cancer therapy. *Exploration, 4*.
- Chen, L., Zhuang, W., Hu, C., Yu, T., Su, X.-F., Liang, Z., Li, G., & Wang, Y. (2020). pH and singlet oxygen dual-responsive GEM prodrug micelles for efficient combination therapy of chemotherapy and photodynamic therapy. *Journal of Materials Chemistry B*.
- Fang, G., Zhang, A., Zhu, L., Wang, Q., Sun, F., & Tang, B. (2022). Nanocarriers containing platinum compounds for combination chemotherapy. *Frontiers in Pharmacology, 13*.
- Hu, L., Xiong, C., Wei, G., Yu, Y., Li, S., Xiong, X., Zou, J.-J., & Tian, J. (2021). Stimuli-responsive charge-reversal MOF@polymer hybrid nanocomposites for enhanced co-delivery of

chemotherapeutics towards combination therapy of multidrug-resistant cancer. *Journal of Colloid and Interface Science, 608*(Part 2), 1882–1893.

- Khaledian, M., Nourbakhsh, M., Saber, R., Hashemzadeh, H., & Darvishi, M. (2020). Preparation and evaluation of doxorubicin-loaded PLA–PEG–FA copolymer containing superparamagnetic iron oxide nanoparticles (SPIONs) for cancer treatment: Combination therapy with hyperthermia and chemotherapy. *International Journal of Nanomedicine, 15*, 6167–6182.
- Qamar, Z., Sartaj, A., Iqubal, M. K., Qizilbash, F. F., Sabir, S., Ali, J., Ali, A., & Baboota, S. (2023). Combination drug loaded lipid-based nanocarriers as treatment entity for battling glioblastoma multiforme. *Journal of Drug Delivery Science and Technology*.
- Yang, D.-C., Wang, S., Weng, X., Zhang, H.-X., Liu, J.-Y., & Lin, Z. (2021). Singlet oxygen-responsive polymeric nanomedicine for light-controlled drug release and image-guided photodynamic-chemo combination therapy. *ACS Applied Materials & Interfaces*.
- Ain, Q. (2019). Current and future aspects of smart nanotheranostic agents in cancer therapeutics. *Nanotheranostics*.
- Dash, S., Swain, S. S., Khuntia, A., Dutta, S., & Sahoo, S. (2024). Nanotheranostics: A cutting-edge technology for cancer management. *Current Pharmaceutical Biotechnology*.
- Dennahy, I. S., Han, Z., MacCuaig, W. M., Chalfant, H., Condacse, A., Hagood, J. M., ... & McNally, L. (2022). Nanotheranostics for image-guided cancer treatment. *Pharmaceutics, 14*.
- Gupta, D., Roy, P., Sharma, R., Kasana, R., Rathore, P., & Gupta, T. K. (2024). Recent nanotheranostic approaches in cancer research. *Clinical and Experimental Medicine, 24*.
- Han, Y., Tang, Q., Jia, G., An, Y., & Ding, Y. (2021). Active targeting nanotheranostic system for dual-modality imaging-guided chemo-/photodynamic therapy of pancreatic cancer.
- Han, Y., Ouyang, J., Li, Y., Wang, F., & Jiang, J. (2019). Engineering H2O2 self-supplying nanotheranostic platform for targeted and imaging-guided chemodynamic therapy. *ACS Applied Materials & Interfaces*.
- Katifelis, H., & Gazouli, M. (2021). Cancer-targeted nanotheranostics: Recent advances and future perspectives. *Nanotechnology in the Life Sciences*.
- Naser, M., Nasr, M. M., & Shehata, L. H. (2024). Updates of nanotheranostics in cancer management: Review. *International Journal of Progressive Sciences and Technologies*.
- Parveen, S., Abira, R., Paikray, S., Sahoo, L., Tripathy, N. S., & Dilnawaz, F. (2024). Recent advancement of nanotheranostics in cancer applications. *Current Drug Delivery*.
- Paliwal, S., Kenwat, R., Maiti, S., & Paliwal, R. (2020). Nanotheranostics for cancer therapy and detection: State of the art. *Current Pharmaceutical Design*.
- Ahmad, R. M., & Mohammad, M. (2021). Towards the use of nanotechnology and pharmacogenomics in personalized medicine.
- Bennani, I., Chefchaouni, A. C., Hafidi, Y., Moukafih, B., El Marrakchi, S., Bandadi, F. Z., Rahali, Y., & El Kartouti, A. (2024). Advancements in the use of nanopharmaceuticals for cancer treatment. *Journal of Oncology Pharmacy Practice*.
- Boehnke, N., & Hammond, P. (2021). Power in numbers: Harnessing combinatorial and integrated screens to advance nanomedicine. *JACS Au, 2*, 12–21.
- Chen, D., Liu, X. W., Lu, X., & Tian, J. (2023). Nanoparticle drug delivery systems for synergistic delivery of tumor therapy. *Frontiers in Pharmacology, 14*.
- Eskandar, K. (2025). Nanotechnology in cancer treatment: Innovative approaches to overcoming drug resistance in tumors. *Indonesian Journal of Cancer Chemoprevention*.
- Hristova-Panusheva, K., Xenodochidis, C., Georgieva, M., & Krasteva, N. (2024). Nanoparticle-mediated drug delivery systems for precision targeting in oncology. *Pharmaceuticals, 17*.
- López-Estévez, A. M., Lapuhs, P., Pineiro-Alonso, L., & Alonso, M. J. (2023). Personalized cancer nanomedicine: Overcoming biological barriers for intracellular delivery of biopharmaceuticals. *Advanced Materials*.
- Shahrukh, S., Jain, N., Shah, S., Famta, P., Srinivasarao, D. A., Khatri, D., Asthana, A., Singh, S. B., Raghuvanshi, R., & Srivastava, S. (2023). Aptamer-guided nanomedicine strategies in prostate cancer: Targeting and diagnosis. *Journal of Drug Delivery Science and Technology*.
- Mohammadzadeh, S., Rahiman, N., Hashemi, S. R., & Hadi, A. (2023). Poly-γ-glutamic acid nanoparticles as an adjuvant and antigen delivery system for enhancing immune responses. *International Journal of Pharmaceutics, 632*, 122650.
- Wang, Q., Qian, C., & Li, T. (2019). Nanoparticulate carriers used as vaccine adjuvant-delivery systems. *Pharmaceutical Research, 36*(3), 56.
- Zhang, X., Liu, L., Wang, Y., & Liu, X. (2023). pH-responsive poly(amino acid) nanoparticles as potent antigen carriers for cytotoxic T-cell responses. *Biomaterials Science, 11*(4), 972–984.
- Zhu, X., & Cui, J. (2023). Uptake and quantification of antigen carried by PLGA nanoparticles in vitro and in vivo. *Nanomedicine: Nanotechnology, Biology and Medicine, 47*, 102642.

- Côté-Cyr, M., Zottig, X., & Archambault, D. (2022). Self-assembly of flagellin into immunostimulatory nanoparticles for vaccine applications. *Vaccine, 40*(15), 2163–2172.
- Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021). Lipid nanoparticles for mRNA delivery. *Nature Reviews Materials, 6*(12), 1078–1094.
- Trollmann, M., & Böckmann, R. A. (2022). mRNA–lipid nanoparticle phase transition: Endosomal escape and transfection mechanism. *Biophysical Journal, 121*(17), 3309–3320.
- Yoo, J., Faisal, S. M., Kim, M., & Kim, J. (2024). A novel less-toxic, lymphoid tissue-targeted lipid nanoparticle for efficient mRNA delivery. *Advanced Drug Delivery Reviews, 200*, 114534.
- Han, X., Alameh, M.-G., Wang, Y., & Weissman, D. (2023). Adjuvant lipidoid-substituted lipid nanoparticles for mRNA vaccines. *Molecular Therapy, 31*(2), 413–429.
- Yang, H., Bai, J., Li, J., & Wang, Y. (2024). Biodegradable lipid-modified poly(guanidine thioctic acid) for enhanced mRNA vaccine delivery. *Biomaterials, 296*, 122077.
- Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021). mRNA vaccines for infectious diseases: Principles, delivery and clinical translation. *Nature Reviews Drug Discovery, 20*(11), 817–838.
- Pilkington, E. H., Suys, E. J. A., Trevaskis, N. L., & McMillan, N. A. J. (2021). From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases. *Acta Biomaterialia, 131*, 16–40.
- Li, J., Xiao, L., Chen, Z., Fan, L., Wang, W., Guo, R. L., ... & Li, B. (2024). A spike-based mRNA vaccine that induces durable and broad protection against porcine deltacoronavirus in piglets. *Journal of Virology, 98*(5), e00535-24.
- Curley, S. M., & Putnam, D. (2022). Biological nanoparticles in vaccine development. *Frontiers in Bioengineering and Biotechnology, 10*, Article 867119.
- Zhou, W., Jiang, L., Liao, S., Wu, F., Yang, G., Hou, L.-T., ... & Zhang, Y. (2023). Vaccines' new era—RNA vaccine. *Viruses, 15*(8), 1760.
- Aguilar, Z. P., Xu, H., Jones, B., Dixon, J., & Wang, A. Z. (2020). Semiconductor quantum dots for cell imaging. *Fluorescent Materials for Cell Imaging*.
- Ali, A. K., Erten-Ela, S., Ismail, R., & Yavuz, C. (2021). Preparation of blue luminescence gold quantum dots using laser ablation in aromatic solvents. *Applied Nanoscience, 11*, 2779–2791.
- Devi, J. S. A., Anju, S., G M, L., Aparna, R., & George, S. (2024). Luminescent carbon dots versus quantum dots and gold nanoclusters as sensors. *Nanoscale Horizons*.
- Kulakovich, O., Gurinovich, L., Trotsiuk, L. I., Ramanenka, A., Li, H., Matveevskaya, N., & Gaponenko, S. (2022). Manipulation of the quantum dots photostability using gold nanoparticles. *Doklady of the National Academy of Sciences of Belarus*.
- Wagner, A. M., Knipe, J., Orive, G., & Peppas, N. (2019). Quantum dots in biomedical applications. *Acta Biomaterialia*.
- Chokkareddy, R., Kanchi, S., & Inamuddin. (2021). Smart nanodevices for point-of-care applications. *Current Analytical Chemistry, 17*.
- Fang, Y., Wang, Y., Zhu, L., Liu, H., Su, X., Liu, Y., ... & He, N. (2022). A novel cartridge for nucleic acid extraction, amplification and detection of infectious disease pathogens with the help of magnetic nanoparticles. *Chinese Chemical Letters*.
- Mahshid, S. (2023). Translational applications of nanostructured biosensors: Diagnostics at the point of care. *ECS Meeting Abstracts*.
- Markandan, K., Tiong, Y. W., Sankaran, R., Subramanian, S., Markandan, U. D., Chaudhary, V., ... & Walvekar, R. (2022). Emergence of infectious diseases and role of advanced nanomaterials in point-of-care diagnostics: A review. *Biotechnology & Genetic Engineering Reviews*.
- Wu, F., Mao, M., Cai, L., Lin, Q., Guan, X., Shi, X., & Ma, L. (2022). Platinum-decorated gold nanoparticle-based microfluidic chip immunoassay for ultrasensitive colorimetric detection of SARS-CoV-2 nucleocapsid protein. *ACS Biomaterials Science & Engineering*
- Gala, K., & Khattar, E. (2020). An overview on the application of nanodiagnostics in cancer. *Biomedical Research Journal, 7*, 40–44.
- Hariri, M., Alivirdiloo, V., Ardabili, N. S., Gholami, S., Masoumi, S., Mehraban, M. R., Alem, M., Hosseini, R. S., Mobed, A., Ghazi, F., & Alipourfard, I. (2023). Biosensor-based nanodiagnosis of carcinoembryonic antigen (CEA): An approach to classification and precise detection of cancer biomarker. *BioNanoScience, 14*, 429–446.
- Liu, W., Wang, Y., Yang, X., Shen, X., & Shi, L. (2023). The implications of nanodiagnostics and artificial intelligence for detecting oral potentially malignant disorders and oral squamous cell carcinoma. *International Journal of Surgery, 109*, 3248–3250.
- Singh, G., Kaur, H., Sharma, A., Singh, J., Alajangi, H. K., Kumar, S., Singla, N., Kaur, I., & Barnwal, R. (2021). Carbon-based nanodots in early diagnosis of cancer. *Frontiers in Chemistry, 9*.
- Li, Y., Zhu, X., Zhang, H., Lu, Y., Zeng, T., Liu, H., Li, T., Wang, J., & Tang, L. (2023). Nanodiamond in cancer theranostics. *Nano TransMed*.
- Bhattacharya, S., Prajapati, B. G., & Singh, S. (2023). A critical review on the dissemination of pH and stimuli-responsive polymeric nanoparticular systems to improve drug delivery in cancer therapy. *Critical Reviews in Oncology/Hematology, 182*, 103961.
- Sethuraman, V., Janakiraman, K., Krishnaswami, V., & Kandasamy, R. (2021). Recent progress in

stimuli-responsive intelligent nano-scale drug delivery systems: A special focus towards pH-sensitive systems. *Current Drug Targets*.

- Pytlíková, S., Konefał, R., Pola, R., Braunova, A., Lobaz, V., Šlouf, M., Beneš, H., Starenko, D., Běhalová, K., Kovář, M., Etrych, T., Laga, R., & Pechar, M. (2024). Dual thermo- and pH-responsive polymer nanoparticle assemblies for potential stimuli-controlled drug delivery. *ACS Applied Bio Materials, 8*, 271–284.
- Wu, F., Qiu, F., Wai-Keong, S. A., & Diao, Y. (2020). The smart dual-stimuli responsive nanoparticles for controlled anti-tumor drug release and cancer therapy. *Anti-Cancer Agents in Medicinal Chemistry*.
- Hughes, K., Misra, B., Maghareh, M., & Bobbala, S. (2023). Use of stimulatory responsive soft nanoparticles for intracellular drug delivery. *Nano Research, 16*, 6974–6990.
- Raka, S., Belemkar, S., & Bhattacharya, S. (2024). Hybrid nanoparticles for cancer theranostics: A critical review on design, synthesis, and multifunctional capabilities. *Current Medicinal Chemistry*.
- Raheem, M. A., Rahim, M. A., Gul, I., Zhong, X. Y., Xiao, C., Zhang, H., ... & Han, Y. (2023). Advances in nanoparticles-based approaches in cancer theranostics. *OpenNano*.
- Carrese, B., Sanità, G., & Lamberti, A. (2022). Nanoparticles design for theranostic approach in cancer disease. *Cancers, 14*(19).
- Xu, M., Xue, B., Wang, Y., Wang, D., Gao, D., Yang, S., ... & Yuan, Z. (2021). Temperature-feedback nanoplatform for NIR-II penta-modal imaging-guided synergistic photothermal therapy and CAR-NK immunotherapy of lung cancer. *Small, 17*(e2101397).
- Hosseini, S. M., Mohammadnejad, J., Salamat, S., Beiram Zadeh, Z., Tanhaei, M., & Ramakrishna, S. (2023). Theranostic polymeric nanoparticles as a new approach in cancer therapy and diagnosis: A review. *Materials Today Chemistry*.
- Kapoor, D. U., Sharma, J. B., Gandhi, S. M., Prajapati, B. G., Thanawuth, K., Limmatvapirat, S., & Sriamornsak, P. (2024). AI-driven design and optimization of nanoparticle-based drug delivery systems. *Science, Engineering and Health Studies*.
- Edriss, A. A., Yarra, S., Vomo, J. A., Ismael, K., & Elshiekh, Y. B. (2025). AI-powered nano formulation: revolutionizing drug development and delivery. *International Journal of Science and Research Archive*.
- Villaseñor-Cavazos, F. J., Torres-Valladares, D., & Lozano, O. (2022). Modeling and optimization of nanovector drug delivery systems: exploring the most efficient algorithms. *Journal of Nanoparticle Research, 24*.
- Yang, L., Liu, Q., Kumar, P., Sengupta, A., Farnoud, A., Shen, R., ... & Schmid, O. (2024). LungVis 1.0: an automatic AI-powered 3D imaging ecosystem unveils spatial profiling of nanoparticle delivery. *Nature Communications, 15*.
- Heydari, S., Masoumi, N., Esmaeeli, E., Ayyoubzadeh, S. M., Ghorbani-Bidkorpeh, F., & Ahmadi, M. (2024). Artificial Intelligence in nanotechnology for treatment of diseases. *Journal of Drug Targeting, 1–49*.
- Ahamad, N., Bhardwaj, P., Bhatia, E., & Banerjee, R. (2020). Clinical toxicity of nanomedicines. *In: Nanomedicine in Drug Delivery* (pp. 533–560). Springer.
- Li, X., Ma, M., An, N., Yao, X., Yasen, G., Zhong, M., et al. (2025). Lipid-rapamycin nanovaccines overcome the antidrug antibody barrier in biologic therapies. *ACS Nano*.
- Mahaling, B., Baruah, N., & Dinabandhu, A. (2024). Nanomedicine in ophthalmology: From bench to bedside. *Journal of Clinical Medicine, 13*.
- Maina, T., Grego, E. A., Broderick, S., Sacco, R., Narasimhan, B., & McGill, J. (2023). Immunization with a mucosal, post-fusion F/G protein-based polyanhydride nanovaccine protects neonatal calves against BRSV infection. *Frontiers in Immunology, 14*.
- Souto, E. B., Blanco-Llamero, C., Krambeck, K., Kiran, N. S., Yashaswini, C., Postwala, H., et al. (2024). Regulatory insights into nanomedicine and gene vaccine innovation. *Acta Biomaterialia*.
- Straehla, J. P. (2024). Strategies to close the translational gap for nanoscale drug delivery systems. *Molecular Cancer Therapeutics* (Conference Abstract).
- Wagner, D. A., Kelly, S., Petersen, A. C., Peroutka-Bigus, N., Darling, R. J., Bellaire, B., et al. (2019). Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague. *Acta Biomaterialia*.
- Ali, F., Neha, K., & Parveen, S. (2022). Current regulatory landscape of nanomaterials and nanomedicines: A global perspective. *Journal of Drug Delivery Science and Technology*.
- Chaudhari, S., & Panchave, R. (2022). Regulatory and toxicology issues surrounding nanomedicines.
- Csóka, I., Ismail, R., Jójárt-Laczkovich, O., & Pallagi, E. (2021). Regulatory considerations, challenges and risk-based approach in nanomedicine development. *Current Medicinal Chemistry*.
- Damjanovska, G., Karanakov, L., & Georgievska, K. Z. (2023). Nanomedicines and off patent follow-on medicines: EMA regulatory procedures overview. *Macedonian Pharmaceutical Bulletin*.
- De Jong, W. D., Geertsma, R., & Borchard, G. (2022). Regulatory safety evaluation of nanomedical products. *Drug Delivery and Translational Research, 12*, 2042–2047.
- Hertig, J. B., Shah, V., Flühmann, B., et al. (2021). Tackling the challenges of nanomedicines: Are we

ready? *American Journal of Health-System Pharmacy, 78*, 1047–1056.

- Musazzi, U., Franzè, S., Condorelli, F., Minghetti, P., & Caliceti, P. (2023). Feeding next-generation nanomedicines to Europe: Regulatory and quality challenges. *Advanced Healthcare Materials, 12*.
- Nyazema, N. Z., Chanyandura, J. T., & Kumar, P. O. (2023). Nanomedicine and regulatory science: The challenges in Africa. *Frontiers in Biomaterials Science*.
- Ramos, T., Villacis-Aguirre, C. A., López-Aguilar, K. V., et al. (2022). The Hitchhiker's Guide to Human Therapeutic Nanoparticle Development. *Pharmaceutics, 14*.
- Salvi, B. V., Kantak, M., Kharangate, K., et al. (2024). Blind spots in development of nanomedicines. *Technology in Cancer Research & Treatment, 23*.
- Singh, A., Bhardwaj, P., Upadhyay, A. K., et al. (2024). Navigating regulatory challenges in molecularly tailored nanomedicine. *Exploration of BioMat-X*.
- Souto, E. B., Blanco-Llamero, C., Krambeck, K., et al. (2024). Regulatory insights into nanomedicine and gene vaccine innovation. *Acta Biomaterialia*.
- Almeida, A., Günday-Türeli, N., & Sarmento, B. (2021). A scale-up strategy for the synthesis of chitosan derivatives used in micellar nanomedicines. *International Journal of Pharmaceutics*.
- Csóka, I., Ismail, R., Jójárt-Laczkovich, O., & Pallagi, E. (2021). Regulatory considerations, challenges and risk-based approach in nanomedicine development. *Current Medicinal Chemistry*.
- Dormont, F., Rouquette, M., Mahatsekake, C., et al. (2019). Translation of nanomedicines from lab to industrial scale synthesis: The case of squalene-adenosine nanoparticles. *Journal of Controlled Release*.
- Djordjevic, S., González, M. M., Conejos-Sánchez, I., et al. (2021). Current hurdles to the translation of nanomedicines from bench to the clinic. *Drug Delivery and Translational Research*.
- Feng, J., Markwalter, C. E., Tian, C., et al. (2019). Translational formulation of nanoparticle therapeutics from laboratory discovery to clinical scale. *Journal of Translational Medicine*.
- Operti, M. C., Bernhardt, A., Grimm, S., et al. (2021). PLGA-based nanomedicines manufacturing: technologies overview and challenges in industrial scale-up. *International Journal of Pharmaceutics*.
- Patel, D., Patel, N. N., & Patel, J. (2021). Nanomedicine Scale-Up Technologies: Feasibilities and Challenges. In *Emerging Technologies for Nanoparticle Manufacturing*.
- Tang, S., Levy, E. S., Zang, N., et al. (2024). Scaling laws for nanoparticles: Online shape heterogeneity analysis by SEC-MALS. *Journal of Chromatography A*.
- Zhang, J., & Liang, X. (2021). Innovative cancer nanomedicine: Opportunities and challenges. *Scientia Sinica Vitae*.
- de Groot, N. F. (2023). Capturing human environmental DNA: Ethical challenges. *Digital Society*, 2.
- Ellison, H. W. (2024). Human enhancement technologies: Moral compass and legal regulations. *Science of Law*, 2024(2).
- Erden, Y., & Brey, P. (2021). Promoting ethics for human enhancement technologies. *Zenodo*.
- Erden, Y., & Brey, P. (2022). Ethics guidelines for human enhancement R&D. *Science*, 378, 835–838.
- Fernholz, Y., Freidank, J., Zhu, J., Ivanov, I., & Kox, T. (2025). Ethics in GIS: A systematic analysis focusing on privacy and surveillance. *GI_Forum*.
- Gauttier, S., Arias-Oliva, M., Murata, K., & Pelegrín-Borondo, J. (2024). The ethical acceptability of the human enhancement technologies: A cross-country Q-study of the perception of insideables. *Computers in Human Behavior: Artificial Humans*, 100092.
- Ghafur, T., Islam, M. M., Alam, N., & Hasan, M. S. (2020). Health and demographic surveillance system sites: Reflections on global health research ethics. *Journal of Population and Social Studies*, 28, 265–275.
- Macnish, K. (2021). Ethical issues in covert, security and surveillance research. *Advances in Research Ethics and Integrity*, 8, 9–16.
- Rueda, J. (2023). The ethics of doing human enhancement ethics. *Futures*, 103236.
- Ameixa, J., Sala, L., Kočišek, J., & Bald, I. (2024). Radiation and DNA origami nanotechnology: Probing structural integrity at the nanoscale. *ChemPhysChem, 26*.
- Aye, S. L., & Sato, Y. (2022). Therapeutic applications of programmable DNA nanostructures. *Micromachines, 13*.
- Gangrade, A., Stephanopoulos, N., & Bhatia, D. (2021). Programmable, self-assembled DNA nanodevices for cellular programming and tissue engineering. *Nanoscale*.
- Ghosal, S., Bag, S., & Bhowmik, S. (2023). Unravelling the drug encapsulation ability of functional DNA origami nanostructures. *Polymers, 15*.
- Li, G., Chen, C., Li, Y., Wang, B., Wen, J., Guo, M., Chen, M., Zhang, X., & Ke, G. (2024). DNA-origami-based precise molecule assembly and their biological applications. *Nano Letters*.
- Loretan, M., Domljanovic, I., Lakatos, M., Rüegg, C., & Acuna, G. (2020). DNA origami as emerging technology for the engineering of biosensors. *Materials, 13*.

- Singh, R. K., & Deshmukh, R. (2022). DNA nanobots—emerging customized nanomedicine in oncology. *Current Drug Delivery*.
- Wang, J., Zhang, P., Xia, Q., Wei, Y., Chen, W., Li, P., Li, B., & Zhou, X. (2021). Application of DNA origami in nanobiomedicine. *Journal of Southern Medical University, 41*(6), 960–964.
- Zhao, C., Jiang, X., Wang, M., Gui, S., Yan, X., Dong, Y., & Liu, D. (2024). Constructing protein-functionalized DNA origami nanodevices for biological applications. *Nanoscale*.